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Common chronic diseases including cardiovascular disease (CVD) are the 
leading cause of morbidity and mortality in developed countries. These diseases are 
multifactorial in origin with both genetic and environmental components that act 
through a complex network of gene-gene and gene-environment interactions to 
generate the health or disease phenotype. The folate metabolic network plays an 
important role in a variety of fundamental intracellular functions including 
remethylation of homocysteine to methionine, DNA synthesis and repair, DNA 
methylation, protein synthesis and cell-signaling. The overall objective of this work is 
to understand the role of genetic variation in the human folate metabolic network in 
cardiovascular risk. We have focused on five potentially-functional candidate SNPs in 
four genes involved in sequential reactions, namely methylene-tetrahydrofolate 
reductase (MTHFR), methylene-tetrahydrofolate dehydrogenase (MTHFD), 
methionine synthase (MTR), and cystoplasmic serine hydroxymethyl transferase 
(cSHMT). We use data from nested case control studies of cardiovascular disease 
conducted in the framework of two large epidemiological cohort studies, the Nurses’ 
Health Study (NHS) and the Normative Aging Study (NAS). Our main findings are 
the presence of gene-nutrient interaction between folate and the MTHFR 677 
polymorphism in predicting serum homocysteine levels, the presence of gene-gene 
  
interaction between the MTHFR 677 and MTHFD 1958 polymorphisms in predicting 
CVD risk, the presence of gene-gene interaction between the MTHFR 1298 and MTR 
2756 polymorphisms, strengthening of the above two interactions with inclusion of 
serum homocysteine levels in the models, and the partial replication in a nested case-
control study of women of a gene-gene interaction between MTHFR 677 and cSHMT 
1420 polymorphism previously detected in a study on men. In summary, we have 
found evidence for the presence of gene-gene interaction between variants in genes 
encoding sequential reactions in the folate metabolic network. Lack of mediation by 
homocysteine suggests that other folate-related markers need to be studied to 
understand the pathophysiologic route from genotype to disease phenotype. Our 
findings suggest the importance of evaluating gene-gene interactions, especially 
among genes with functional connections, in epidemiologic studies of complex 
disease in general, and cardiovascular disease in particular.  
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CHAPTER 1 
FOLATE METABOLISM AND CARDIOVASCULAR DISEASE: BACKGROUND 
AND SIGNIFICANCE 
 
Cardiovascular Disease: Genetic and Environmental Web 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
in industrialized, developed nations 1. By the year 2020, it is estimated that CVD will 
surpass infectious diseases as the world's leading cause of death and disability 1. CVD 
is multifactorial in origin with both genetic and environmental components. Typically, 
CVD shows some degree of familial aggregation, but it does not segregate in families 
as single gene disorders do. In fact the distribution of disease among individuals, 
families, and populations is a direct consequence of the distribution of interactions 
between the effects of many susceptibility genes and many environmental exposures 2. 
This complex web of interactions works through dynamic, epigenetic, and regulatory 
mechanisms to ultimately become integrated and generate the health or disease 
phenotype 3-8. 
 Traditionally, the epidemiologic study of human disease has focused on 
selected possible risk factors, and determining the degree of contribution of that factor 
to the risk of disease in a population. The field of epidemiology has succeeded in 
determining a considerable number of constitutional as well as modifiable lifestyle 
factors that contribute to a person’s risk of developing cardiovascular disease. These 
so-called “traditional” risk factors include male gender, age, hypertension, diabetes 
mellitus, family history of premature CVD, elevated levels of plasma low-density 
lipoprotein cholesterol, decreased levels of high-density lipoprotein cholesterol, and 
elevated levels of plasma total homocysteine. The study of genetic factors that 
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contribute to human disease has been mostly driven by the “nature vs. nurture” 
paradigm, in which the focus of the investigation is on determination of the competing 
contribution of genetic and environmental factors. The observation that genetic 
variation and environmental exposure variation are elements that work together to 
produce an outcome is well understood in the theory of human genetics, and is 
increasingly being incorporated into the design of epidemiologic studies of disease. 
The completion of the human genome project has provided the full inventory 
of genes that specify all of the components that constitute human cells and has 
therefore provided an unprecedented opportunity to add multiple levels of complexity 
to the study of human disease risk.  Equally important, ongoing initiatives to identify 
and map single nucleotide polymorphisms (SNP) 9, 10 and human haplotypes 10 within 
the human genome offer the possibility of understanding the molecular basis for gene-
environment interactions that determine human phenotypic variation 11. Given the new 
tools and opportunities of the genomic age, investigators have shown that genetic 
factors comprise a considerable amount of interaction among genes, manifested as a 
high level of inter-dependence among genes and an extreme sensitivity to subtle 
background genetic variation 12. The presence of this highly interconnected, highly 
interactive system has been shown in different model systems 13, 14.  
The implication of considering networks as functional systems of action in 
biology is that network elements are highly dependent on the background state of the 
system, and are highly versatile and can assume new roles in the system if conditions 
call for it. In addition, the relationship between a factor and an outcome is not 
necessarily linear. Most of these network-dependent aspects of biological systems 
have been ignored in the study of human disease, and have therefore limited the 
potential for greater understanding of the true interactive mechanisms that underlie the 
development of disease 2.  
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The path from a genotypic variant to an observable clinical outcome is not 
always a straightforward linear relationship. Often, there are intermediate risk factors 
and intermediate phenotypes that are affected by the genotypic variant. Changes in 
homocysteine level due to genotypic variants in the folate metabolism genes and the 
ensuing alteration in endothelial function, blood pressure regulation, and plaque build-
up are examples of these intermediary outcomes (Figure 1.1). Consideration of these 
factors in the design of epidemiologic studies of complex disease can provide valuable 
insights into the pathophysiology.  
Genetic variation in folate metabolism and cardiovascular risk 
The consequences of altered folate homeostasis in neural tube defects are well-
known, and recent studies implicate disrupted folate metabolism in the pathogenesis of 
both cardiovascular disease and cancer. Cytoplasmic folate is needed for the 
biosynthesis of purines, thymidylate, and methionine. These products play a 
fundamental role in remethylation of homocysteine to methionine, DNA synthesis and 
repair, DNA methylation, protein synthesis and cell-signaling. Folate metabolism may 
be disrupted by vitamin deficiency, genetic predisposition, and by medical therapies 
Such metabolic disruptions lead to various biochemical consequences 
including elevated levels of plasma homocysteine (a proposed causal pathway for 
cardiotoxic effects), increased uracil misincorporation into DNA due to disrupted 
thymidylate synthesis, and hypomethylation of DNA due to reduced methylation 
potential by S-adenosyl methionine (SAM) (the latter two are proposed causal 
pathways for carcinogenic effects). Thus, genetic polymorphisms in enzymes that 
regulate the distribution of intracellular forms of folate and control serum 
homocysteine levels have the potential to produce diverse clinical consequences 
including heart disease and cancer. 
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Figure 1.1. The pathway postulated to connect genotype to phenotype in 
atherosclerosis. (abbreviations: HCY, homocysteine; CABG, coronary artery bypass 
graft; CVD, cardiovascular disease) 
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Homocysteine is hypothesized to be a key player in the pathogenesis of 
cardiovascular disease 15. It is a sulphur amino acid that is formed by the 
demethylation of the essential amino acid methionine via S-adenosylmethionine 
(SAM or AdoMet) and S-adenosylhomocysteine (SAH or AdoHcy) 16. SAM is the 
methyl donor in numerous methylation reactions including DNA and RNA 
methylation, and is synthesized from methionine in a reaction catalyzed by the 
enzyme, methionine adenosyltransferase (MA). Homocysteine is in turn metabolized 
through two separate pathways, transsulfuration and remethylation (Figure 1.2). The 
first step in the transsulfuration pathway is the condensation of homocysteine and 
serine to produce cystathionine. This step is catalyzed by cystathionine β-synthase 
(CBS). Cystathionine is subsequently hydrolyzed to cysteine by γ-cystathionase. 
Homocysteine can be remethylated to methionine by two different enzymatic 
reactions: methionine synthase (MTR), with 5-methyltetrahydrofolate (5-methyl-THF) 
as methyl donor; or betaine homocysteine methyltransferase (BHMT), with betaine 
(trimethylglycine) as methyl donor. 5-methyl-THF is in turn formed by the reduction 
of 5,10-methylene-tetrahydrofolate, a reaction that is catalyzed by the enzyme 5,10-
methylene tetrahydrofolate reductase (MTHFR). The reversible conversion of serine 
and tetrahydrofolate (THF) to glycine and 5,10-methylene-THF is catalyzed by 
cytosolic serine hydroxymethyltransferase (cSHMT). Methylenetetrahydrofolate 
dehydrogenase (MTHFD) catalyzes three sequential reactions in the conversion of 
derivatives of THF. Given the complexity of the folate and homocysteine metabolism 
network, the genes coding for the various enzymes detailed above are plausible 
candidates for consideration in studies of cardiovascular disease risk.  
MTHFR is one of the first genes whose alleles have been linked to alterations 
in serum homocysteine concentration and cardiovascular risk. In 1988, a variant of the 
MTHFR enzyme was found to be associated with decreased enzyme activity and 
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reduced stability after heating17. This thermolabile variant of MTHFR was later found 
to be due to a single base nonsynonymous substitution of C to T at nucleotide 677 
(causing an alanine to valine substitution at amino-acid position 222), and to be more 
prevalent in patients with cardiovascular disease18, 19. The association of this 
polymorphism with coronary artery disease was recently established in a large meta-
analysis 20 involving 11,162 cases and 12,758 controls. This meta-analysis estimated 
that the odds ratio (OR) for 677 TT genotype vs. CC genotype was 1.16 (95% 
confidence interval (CI) 1.05, 1.28) 21. The relation between MTHFR 677C→T and 
cardiovascular disease clearly shows evidence of a gene-nutrient interaction, as the 
associations among the polymorphism, cardiovascular disease, and elevated 
homocysteine are stronger in persons and in populations with low folate status 21-23. 
MTHFR variation due to the 677C→T polymorphism is a strong genetic determinant 
of homocysteine concentration that has been consistently observed in numerous 
studies, but it accounts for only 25% of the mild hyperhomocysteinemia observed in 
subjects with vascular disease 24. This indicates that additional mutations in the 
MTHFR gene (for example MTHFR 1298A→C, studied herein) or in other genes 
within the folate metabolic network may contribute to variation in homocysteine 
concentrations 16.  
The association of common polymorphisms in other genes of the folate 
metabolic network with arteriosclerosis has been analyzed in only a limited number of 
studies and remains to be determined 16. Another gene encoding a critical enzyme in 
the folate metabolic network is methionine synthase (MTR). MTR, a vitamin B12-
dependent enzyme, catalyzes the remethylation of homocysteine to methionine using a 
methyl group donated by 5-methyl-THF, which is the major circulating form of folate 
in the human body (Figure 1.2). It is therefore biologically plausible that functional 
genetic variants of the MTR gene would alter the homocysteine and folate levels and 
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in turn affect the pathogenesis of vascular disease. The MTR gene was simultaneously 
cloned by three groups25-27 and analyzed for the presence of common polymorphisms. 
The only common polymorphism in the MTR gene reported to date is an A→G 
transition at nucleotide 2756 (MTR 2756 A→G ) in the open reading frame of the 
gene, which results in replacing an aspartic acid (D) residue with a glycine (G) at 
codon 919 (D919G), a potentially functional site of the protein 28. Studies on the 
biological effect of this polymorphism have been mostly case-control or cross-
sectional in design and also limited by sample size. These studies yielded inconsistent 
results 29-33, and most have focused on the single effect of the MTR polymorphism on 
cardiovascular risk without consideration of the plausible interaction with the MTHFR 
polymorphisms. In this study, we plan to consider this interaction. 
 Investigating interactions between genetic polymorphisms is one of the 
primary objectives of this work. Many of the biologically-relevant SNPs are part of a 
functional biochemical network, and therefore interact with other elements of the 
network2, 12. While evaluating multiple interactions is severely limited by the power 
issues resulting from small sample size in many cross-sectional epidemiologic studies, 
using the data obtained in the large nested case-control study within the Normative 
Aging Study, we have previously shown that such interactions exist and can be 
detected between different SNPs of the folate metabolic network 34 (Figure 1.2).  
Previous findings from the Normative Aging Study (NAS) relate to a 
polymorphism in the human cytoplasmic serine hydroxymethyltransferase (cSHMT 
1420C→T) gene that affects the regulation of intracellular folate 35. Factors affecting 
the activity of the cSHMT enzyme, including the polymorphism in question, are 
expected to relate to the flux of one-carbon folate forms within the cell 36, and 
ultimately may be associated with health outcomes including neural tube defects, 
cardiovascular disease and cancer. Intracellular folate cofactors exist in limited 
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concentrations and numerous folate- dependent reactions compete for available folate. 
The competition for 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) is 
keen given the role of this substrate in three known reactions, and the cSHMT enzyme 
is likely to be key given its direct effects on the supply or depletion of 5,10-
methyleneTHF. Prior research has indicated that complete absence of the functional 
domain where the cSHMT polymorphism resides causes disruptions in one-carbon 
homeostasis 37. Under these circumstances (absence of functional domain in cSHMT) 
reaction pressure may favor serine synthesis, affecting the thymidylate cycle with 
resultant increased uracil misincorporation into DNA 38. At the same time, the cSHMT 
polymorphism may lead to the depletion of 5,10-methyleneTHF and subsequently, to 
the depletion of 5-methylTHF with two results. First, as a required cofactor for 
homocysteine remethylation, depleted 5-methylTHF leads to homocysteine 
accumulation, and second, reduced homocysteine remethylation leads to reduced 
production of SAM and therefore to reduced SAM-mediated methylation (thus, 
hypomethylation of DNA). Recent evidence suggests the cSHMT 1420C→T 
polymorphism’s putative action might be related to sumoylation of the cSHMT 
protein, affecting transport from the cytoplasm to the nucleus (Stover P, personal 
communication). In summary, the metabolic disruptions brought about by the cSHMT 
polymorphism have the potential to play a role in the pathogenesis of cardiovascular 
disease and cancer. 
Although the functional consequences of the cSHMT 1420C→T polymorphism 
are not proved, studies demonstrate effects on biochemical phenotype 39, leukemia 
risk40, and cardiovascular risk41. In a study of mothers of neural tube defect cases, Heil 
and colleagues reported lower plasma homocysteine in women with the cSHMT 
1420C→T CT or TT genotypes compared to women with the CC genotype 39. In a 
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Figure 1.2. Folate metabolic network and homocysteine metabolism. : (BHMT: 
betaine-homocysteine methyltransferase, MTHFR: Methylenetetrahydrofolate 
reductase, cSHMT: Cytoplasmic serine hydroxymethyltransferase, B6: Vitamin B6, 
B12: vitamin B12; CL: cysthationine lyase, ; CBS: cysthationine β-synthase, MTHFD: 
Methylenetetrahydrofolate dehydrogenase, ; MS: Methionine synthase) 
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study of 71 individuals diagnosed with acute lymphocytic leukemia (ALL), both the 
cSHMT 1420C→T CT genotype and the TT genotype were associated with a reduced 
risk of ALL (odds ratios [OR] 0.48; 0.31, respectively) 40. In a nested case control 
study of 535 CVD cases in the Normative Aging Study41 our group found a strong 
inverse association of the cSHMT 1420C→T TT genotype (compared to CT and CC) 
with cardiovascular disease risk (OR = 0.45; 95% CI: 0.25, 0.81) among men with the 
MTHFR C→T CC genotype. However, the cSHMT 1420C→T TT genotype was 
associated with an increased risk of CVD among men heterozygous (OR = 1.59; 95% 
CI: 1.40, 1.80) or homozygous (OR = 3.11; 95% CI: 1.52, 6.36) for the variant of 
MTHFR 677C→T (CT, TT, respectively). Thus, the cSHMT polymorphism affects 
cardiovascular disease risk, with strong evidence for a gene-gene interaction (p<0.05), 
making a compelling case for further studies to confirm this finding, and to explore 
the biochemical phenotype to reveal the metabolic consequences of this genetic 
variation.  
Research Questions  
The overall objective of the research presented herein is to understand the role 
of genetic variation in specific genes in the folate metabolic network in relation to the 
pathogenesis of cardiovascular disease. The studies describe the extent of genetic 
variation in selected genes encoding proteins involved in folate metabolism, the effect 
of that variation on cardiovascular risk, and the role of changes in folate and 
homocysteine as the intermediary between the genotype and the disease phenotype. 
Our analysis is guided by the conceptual framework summarized in Figure 1.3, which 
has been divided into three sections to reflect the three chapters of the dissertation.  
The work is focused on four genes that are directly involved in homocysteine 
remethylation or transsulfuration or that indirectly provide the substrates needed for 
these reactions. These genes are important in maintaining adequate intracellular folate 
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pools, and therefore contribute to the de novo biosynthesis of purines and thymidylate 
as well as DNA methylation. This dissertation investigates five potentially-functional 
candidate single nucleotide polymorphisms in four genes related to folate metabolism, 
including MTHFR 677C→T and 1298A→C, cSHMT 1420C→T, MTR 2756A→G, 
and MTHFD 1958G→A.  
The three chapters address the following specific research questions:  
1.  To investigate the single, joint, and interactive effects of three single-
nucleotide polymorphisms in the MTHFR and cSHMT genes on plasma homocysteine 
levels and cardiovascular disease in a case control study of cardiovascular disease in 
women (NHS), and to explore whether these effects are modified by plasma levels of 
folate, vitamin B6 and vitamin B12 (Figure 1.3, section B). 
2. and 3.  To examine the association of MTR 2756A→G, and MTHFD 
1958G→A with plasma homocysteine levels and with cardiovascular disease in the 
Normative Aging Study, while considering the effects of gene-gene interaction, 
mediation by homocysteine levels, and effect modification by folate levels (Figure. 
1.3: sections A and C). 
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Figure 1.3. Pathway diagram demonstrating the relation between MTHFR, cSHMT, 
MTHFD, and MTR genotypes, serum homocysteine level, and cardiovascular disease 
risk, including the role of dietary and serum folate as potential effect modifiers (gene-
nutrient interaction).  (MTHFR: Methylenetetrahydrofolate reductase, cSHMT: 
Cytoplasmic serine hydroxymethyltransferase, MTHFD: Methylenetetrahydrofolate 
dehydrogenase, MTR: Methionine synthase) 
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CHAPTER 2 
MTHFD1 1958G→A AND MTHFR 677C→T IN RELATION TO SERUM 
HOMOCYSTEINE CONCENTRATION AND CARDIOVASCULAR DISEASE 
RISK: THE NORMATIVE AGING STUDY 
 
 
Abstract 
Genetic variants in enzymes of the folate metabolic network are associated 
with a variety of outcomes. A well-known genetic polymorphism in 
methylenetetrahydrofolate reductase (MTHFR 677C→T) is associated with higher 
homocysteine level and cardiovascular disease (CVD) risk. Methylenetetrahydrofolate 
dehydrogenase (MTHFD1) catalyzes the interconversion of tetrahydrofolate 
derivatives needed for purine, thymidylate and methionine synthesis. The MTHFD1 
1958G→A polymorphism is associated with an increased risk of neural-tube defects. 
In a matched case-control study nested within the Normative Aging Study, we studied 
the association of these two polymorphisms with homocysteine and CVD risk, 
considering gene-nutrient and gene-gene interactions. In regression models with 
homocysteine as an outcome, folate deficiency and MTHFR 677 variant T allele were 
significantly associated with homocysteine levels. There was also a significant 
MTHFR-folate interaction in models predicting homocysteine concentration. No such 
interaction was observed for MTHFD1 polymorphism. In adjusted conditional logistic 
models, MTHFD1 GA/AA (vs. GG) had a statistically non-significant protective effect 
on CVD risk (OR 0.8; 95% CI 0.6, 1.1), and this effect was similar in folate 
subgroups. A gene-gene interaction between the two polymorphisms was observed 
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(overall p=0.24, individual coefficient p values .09 and .35). The increased risk of 
CVD association with the MTHFR  677C→T TT genotype was only observed among 
men with MTHFD1 GA/AA genotype (OR 1.6, 95% CI 1.1, 2.4), and was not evident 
among those with MTHFD1 GG genotype (OR 1.1, 95% CI 0.6, 2.2).  The MTHFR 
677C→T CT genotype increased CVD risk among men with MTHFD1 GA/AA 
genotype (OR 1.2; 95% CI 0.9, 1.7), but had little or no effect in men with the 
MTHFD1 GG genotype (OR 0.8; 95% CI 0.5, 1.3). The findings support a gene-gene 
interaction between two important genes of the folate metabolic network. This 
interaction does not seem to be mediated by alterations in plasma homocysteine levels.  
 
Introduction 
Genetic variants in enzymes of the folate metabolic network are associated 
with a variety of disease outcomes, including cardiovascular disease (CVD)1. The 
most widely-studied variant is the MTHFR 677 C→T polymorphism. This common 
polymorphism results in an alanine to valine substitution in position 222 of the 
encoded protein, is relatively common in populations of Caucasian descent, and is 
associated with lower catalytic activity of the MTHFR enzyme2. Epidemiologic 
studies have demonstrated that the MTHFR 677 C→T polymorphism is associated 
with increased serum homocysteine concentration and CVD risk, especially in folate-
deficient populations, indicating a gene-nutrient interaction3. This MTHFR genotype 
explains some of the variation in disease risk observed in different populations, but 
since folate metabolism and homocysteine remethylation are mediated by a complex 
network of enzymes, attention has shifted to include other genes.  
Another important enzyme in the folate metabolic network is 
methylenetetrahydrofolate dehydrogenase (MTHFD1), a trifunctional enzyme that 
catalyzes the sequential interconversion of tetrahydrofolate derivatives required for 
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purine, thymidylate, and methionine synthesis. The trifunctional enzyme comprises 
the following functions: N10-formyltetrahydrofolate synthetase; N5,N10-
methenyltetrahydrofolate cyclohydrolase; and N5,N10-methylenetetrahydrofolate 
dehydrogenase4. The final step produces a key substrate in folate metabolism, namely 
5,10-methylenetetrahydrofolate. A common polymorphism in the MTHFD1 gene, 
653R→Q, resulting from an A to G transition at nucleotide position 1958, has been 
detected in the synthetase domain of the protein5. The effect of this polymorphism on 
the catalytic activity of the enzyme is unknown. Several recent reports investigated 
this variant in relation to developmental outcomes and chronic diseases, and reported 
that AA variants were at increased risk of neural tube defects and placental abruption 
compared to the GA/GG genotypes4-10. The variant had little or no association with the 
risk of colorectal cancer 11. In the three studies that investigated the association of the 
MTHFD1 1958G→A genotype with homocysteine levels, no statistically significant 
relation was observed between the variant allele and serum homocysteine levels11-13. 
A key intersection in folate metabolism is 5,10-methylenetetrahydrofolate 
(5,10-methyleneTHF), which is the substrate for three enzymes: methyleneTHF 
reductase (MTHFR), cytosolic serine hydroxymethyl transferase (cSHMT), and 
thymidylate synthase (TS). TS uses 5,10- methyleneTHF as a substrate to synthesize 
the thymidine residues needed for DNA replication and repair11. cSHMT uses 5,10-
methyleneTHF as a substrate in the interconversion of glycine to serine14. MTHFR 
uses 5,10- methyleneTHF for provision of 5-methylTHF to the homocysteine 
remethylation reaction. Genetic variants of MTHFR or MTHFD1 that result in reduced 
enzyme activity or changes in gene expression are hypothesized to result in higher 
serum homocysteine concentration through decreased availability of 5-methylTHF for 
folate-dependent remethylation of homocysteine. In addition, since these two enzymes 
catalyze sequential steps at a critical point in the folate metabolic network, we 
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hypothesized a biological interaction between the enzymes. 
The objective of this study was to evaluate the relation of MTHFR 677C→T 
and MTHFD1 1958G→A genotypes with serum homocysteine concentration and with 
cardiovascular disease risk: prior research on MTHFR supports increased risk 
associated with the T allele, and prior research on MTHFD1 suggests increased risk 
associated with the A allele. We also sought to investigate the MTHFD1 by MTHFR 
interaction. Effects on CVD risk are hypothesized to be mediated in part by 
homocysteine elevation (a biological marker of folate-dependent methylation), thus 
the role of homocysteine as a mediator was assessed. Finally, folate status is a possible 
effect modifier of these associations, and thus gene-nutrient interactions were 
considered.  
 
Methods 
The study population and data collection have been described previously15. In 
brief, a nested case—control study was conducted within the prospective Normative 
Aging Study (NAS) cohort. Initially 2,280 men aged 21-81 (mean age 42 years at 
study entry) were included in the study: intake into the cohort occurred between 1961 
and ’63. Exclusion criteria included past or current chronic conditions, including 
coronary heart disease, hypertension, diabetes, cancer, peptic ulcer, gout, asthma, 
chronic bronchitis, and chronic sinusitis16. Participants have undergone comprehensive 
clinical examinations at 3- to 5-year intervals, with a response rate of greater than 90% 
for mailed questionnaires. The overall annual attrition rate from all causes was less 
than 1%.   
From 1961 to 1998, 749 incident cases of cardiovascular disease (CVD) 
occurred (including coronary heart disease (CHD) and stroke). Possible occurrences of 
CHD, including angina pectoris and nonfatal myocardial infarction (MI), were 
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evaluated based on medical records and physician examination17. Possible occurrences 
of stroke were confirmed by neurologists who reviewed individual medical records18. 
CHD or stroke mortality was confirmed by death certificates, which were coded 
according to the eighth revision of the International Classification of Diseases18. 
About six percent of cases had only stroke. DNA was available only for more recent 
cases, thus 535 incident CVD cases were studied. The cases without DNA were older 
at study entry, had slightly higher systolic blood pressure and greater cumulative 
smoking exposure. 
A total of 1,048 matched controls were selected from the cohort by risk set 
sampling, and two controls were matched to each case by age at onset and birth period 
(in five-year intervals) of the case. The final list of distinct individuals selected 
included 535 cases and 547 non-cases, with a maximum of 2 controls matched to each 
case. The study was approved by the Brigham and Women’s Hospital Human Subjects 
committee, the Veterans’ Administration R & D committee, and the Cornell 
University Committee on Human Subjects. 
 At each follow-up examination, extensive information on lifestyle 
variables and physical examination results were collected and a blood sample was 
drawn and stored. Beginning in 1987, men completed the Willett semi-quantitative 
food frequency questionnaire (FFQ) on dietary intake in the past year. Estimations of 
dietary intake, including B vitamins, were derived from the FFQ using software 
developed by the Nurses Health Study19. At least one FFQ measurement was available 
prior to the date of diagnosis for about half of the CVD cases (246 out of 535) and half 
of the non-cases (307 out of 547). Lipids were assayed over the course of the follow-
up as follows: serum cholesterol was assayed enzymatically (SCALVO Diagnostics, 
Wayne, New Jersey); HDL cholesterol was measured in the supernatant after 
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precipitation of the LDL cholesterol and very low density lipoprotein fractions with 
dextran sulfate and magnesium, using the Abbott Biochromatic Analyzer 100 (Abbott 
Laboratories, South Pasadena, California); triglyceride was measured with a Dupont 
ACA discrete clinical analyzer (Biomedical Products Department, Dupont Company, 
Wilmington, Delaware). Total plasma homocysteine was assayed in an unselected 
subset of stored blood samples. Plasma samples were stored at -80◦ C, and transferred 
to the Jean Mayer USDA Human Nutrition Research Center on Aging where they 
were analyzed. Total homocysteine in plasma was determined by an adaptation of the 
method described by Araki and Sako20. The coefficient of variation for this assay was 
4.0%. Homocysteine data were available for about 54% of cases and 72% of controls. 
Most (93%) of the plasma homocysteine data were obtained from blood samples 
collected at a regular study visit after the CVD event had occurred.  
In 1999, DNA was extracted from stored frozen buffy coat of 7 cc whole 
blood, using the Qiamp DNA blood kits (Qiagen, Valencia CA): DNA was 
successfully extracted for 1,584 cohort participants. Genotypes of the two 
polymorphisms (MTHFR 677C→T, and MTHFD1 1958G→A) were determined by 
the TaqMan procedure using the allelic discrimination technique (ABI Prism 7900 
Sequence Detection System, Applied Biosystems, Foster City, CA). The primers and 
probes for both polymorphisms were created according to standard methods for the 
TaqMan procedure.  
Student’s t-test and chi-square were used to compare means of continuous and 
categorical variables, respectively, and to assess Hardy-Weinberg equilibrium. 
Conditional logistic regression, which accounts for the matched design, was used to 
assess the relation of genotype with disease risk. Two-way interaction terms were 
included in the adjusted conditional logistic regression model to evaluate the presence 
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of gene-gene interaction. To assess the inclusion of interaction terms in the models, a 
likelihood ratio test was used to calculate the global p-value comparing the model with 
interaction terms to that without. The coefficients provided by this analysis were used 
to calculate the effect size for each genotype in subgroups of the other genotype. To 
examine the influence of genotypes on serum levels of homocysteine, ANOVA was 
used to calculate the mean level of homocysteine in each genotype subgroup after 
adjusting for age at homocysteine measurement. All p-values presented are from two-
tailed tests and all analyses were performed using SAS v. 9.0 (SAS Institute, Cary, 
NC). 
 
Results 
The pattern of cardiovascular risk factors was consistent with greater CVD risk 
in cases compared to controls (Table 2.1). The pattern of vitamin intake, as assessed 
by total dietary intake of folate, vitamin B6, and vitamin B12 by FFQ, was similar 
between cases and controls, and mean plasma homocysteine concentration was 0.5 
µmol/L higher in cases. Genotype had little or no association with the traditional 
cardiovascular risk factors (data not shown).  
Among controls, the frequency of the variant allele was 34.7% for the MTHFR 
T allele and 47.1% for the MTHFD1 A allele (Table 2.2), similar to reports from other 
studies3, 6, 11, 12. Both MTHFR 677C→T and MTHFD1 1958G→A were in Hardy-
Weinberg equilibrium (P value = 0.97 and 0.15, respectively).  
Homocysteine was measured in a subset of all cases and controls due to the 
date of the blood draw for this assay (early 1990s), thus serum variables are available 
on 620 (60%) of the full case-control study population. In regression models with 
homocysteine as the dependent variable and ignoring case-control status, the MTHFR 
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677C→T polymorphism and folate status (coded as tertiles of serum folate based on 
the distribution in controls: tertile cutpoints were 7.40 and 12.50 ng/ml) were both 
statistically significantly associated with serum homocysteine levels (P= 0.0005 and  
P < 0.0001, respectively), and there was a statistically significant two-way interaction 
between the MTHFR 677C→T genotype and serum folate (P= 0.01). The least-squares 
mean of serum homocysteine was greatest in men with the MTHFR 677C→T TT 
genotype compared to men with the CT or CC genotypes (11.6 nmol/l [95% CI 11.2, 
12.7], 10.3 nmol/l [95% CI 9.9, 10.7], and 10.2 nmol/l [95% CI 9.7, 10.7], 
respectively). Serum folate was inversely associated with serum homocysteine such 
that men in the lowest serum folate tertile had the highest homocysteine levels. The 
mean serum homocysteine concentration by serum folate tertile (low to high) was: 
12.7 nmol/l (95% CI 12.2, 13.2), 10.6 nmol/l (95% CI 9.96, 11.2), and 9.20 nmol/l 
(95% CI 8.6, 9.8). Finally, among men with the lowest serum folate, men with the 
MTHFR 677C→T TT genotype had significantly higher serum homocysteine levels in 
comparison to all other groups (mean in this subgroup was 14.9 nmol/L [95% CI 13.8, 
16.0]; P<0.01 for all comparisons) (Table 2.3).  
The MTHFD1 polymorphism had little or no association with homocysteine 
(P= 0.89), but there was statistical evidence for an interaction between the MTHFR 
677C→T and MTHFD1 1958G→A genotypes (P= 0.02). Mean homocysteine in 
MTHFR genotype groups varied by the MTHFD1 genotype: in the MTHFD1 GG 
genotype group, serum homocysteine concentrations of 9.7, 10.3 and 12.8 nmol/L 
were observed for MTHFR 677 CC, CT, and TT genotypes, respectively.  In the 
MTHFD1 GA/AA genotype group, serum homocysteine concentrations of 10.6, 10.4, 
and 11.1 nmol/L were observed for MTHFR 677 CC, CT, and TT genotypes, 
respectively. Men with MTHFD1 GG/MTHFR TT genotype (mean = 12.8 nmol/L) had 
statistically significantly higher homocysteine compared to four of the other genotypes 
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(P < 0.05 for all comparisons). There was no statistical evidence for a three-way 
interaction between the two polymorphisms and folate tertiles in relation to 
homocysteine (P=0.2) (data not shown).  
In unadjusted conditional logistic regression models assessing the genotype—
CVD association, both MTHFD1 1958G→A AA vs. GG and GA vs. GG had similar 
associations: the odds ratios (OR) were 0.84 (95% CI 0.6, 1.2) and 0.88 (95% CI 0.7, 
1.1), respectively. Further models therefore considered the combined MTHFD1 
1958G→A AA/GA genotype in comparison to the GG genotype. The MTHFR 
677C→T polymorphism has a well-documented graded effect on phenotype2, hence 
CT and TT were considered separately in comparison to the CC genotype.  
MTHFR 677C→T CT vs. CC increased risk by 13% (OR 1.13; 95% CI 0.9, 
1.4) and TT vs. CC increased risk by 54% (OR 1.54; 95% CI 1.1, 2.2). Adjustment for 
covariates had little or no effect on these estimates. In the subgroup with measured 
serum folate (~60% of total group) serum folate deficiency (defined as serum folate 
level < 7.5 nmol/L) was not an effect modifier of the MTHFR-CVD association (P 
values for the genotype*folate interaction terms were 0.5 and 0.9). 
There was little or no association of MTHFD1 genotype with CVD risk in 
unadjusted models (AA/GA vs. GG OR 0.87; 95% CI 0.7, 1.1), and adjusting for 
covariates had little or no effect on model coefficients. There was no evidence for an 
interaction between folate deficiency and the MTHFD1 polymorphism.  
The addition of the MTHFR genotype to the MTHFD1-CVD model did not 
affect the coefficients for the MTHFD1 polymorphism, but in models evaluating the 
interaction of the two genotypes (Table 2.4), there was weak statistical evidence for an 
interaction (P value = 0.24 for the set of interaction coefficients, individual coefficient 
P values of 0.36, 0.095). The effect sizes for the MTHFR polymorphism within strata 
of the MTHFD1 variant were calculated from model coefficients. The deleterious 
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effect of homozygosity for the MTHFR T allele was observed in men with MTHFD1 
GA/AA genotype (OR 1.6, 95% CI 1.1, 2.4), but not in men with MTHFD1 GG 
genotype (OR 1.1, 95% CI 0.6, 2.2).  The MTHFR 677C→T CT genotype had a 
deleterious effect in men with MTHFD1 GA/AA genotype (OR 1.2; 95% CI 0.9, 1.7) 
and a statistically non-significant inverse effect in men with MTHFD1 GG genotype 
(OR 0.8; 95% CI 0.5, 1.3). Further adjustment for the cSHMT 1420C→T genotype 
had little or no effect on these findings. There was no evidence for a three-way 
interaction between serum folate concentration, the MTHFR 677 polymorphism, and 
the MTHFD1 1958 polymorphism (P value = 0.6 and 0.5 for the three-way interaction 
terms).  
To investigate the mediating role of homocysteine levels on the genotype-CVD 
relationship, serum homocysteine concentration was added to the conditional logistic 
regression models. Paradoxically, the addition of homocysteine to the model 
strengthened the interaction between the MTHFD1 and MTHFR polymorphisms; the 
overall P value for the interaction model dropped to 0.14, and the individual 
regression coefficients P values decreased to 0.058 and 0.21 (Table 2.5). Adjusting for 
serum homocysteine slightly attenuated the effect of homozygosity for MTHFR T 
allele in men with MTHFD1 GA/AA genotype (OR 1.4; 95% CI 0.8, 2.5) (Table 2.5). 
 
Discussion 
We studied the association of two genetic polymorphisms in the folate 
metabolic network (MTHFR 677 C→T and MTHFD1 1958G→A) with cardiovascular 
disease in this nested case-control study of the Normative Aging Study cohort. The 
main clinical endpoint is cardiovascular disease, with serum homocysteine level 
studied as a secondary outcome and as a mediating risk factor. We investigated the 
main and interactive effects of two single-nucleotide polymorphisms in the MTHFR 
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Table 2.1. Characteristics at study entry of cases and controls, Normative Aging 
Study, 1961-19981. 
 
Variable Cases Controls 
Questionnaire and Physical Exam2 
BMI 
Alcohol intake, usual ≥ 2/day (%) 
Current smokers (%) 
Duration of smoking (years) 
Cumulative smoking (pack-years) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Food Frequency Questionnaire3 
Folate (µg/d) 
Vitamin B6 (mg/d) 
Vitamin B12 (µg/d) 
Serum Biomarkers4 
Total cholesterol (mg/dL)5 
HDL cholesterol (mg/dL) 5 
Triglycerides (mg/dL) 
Folate (ng/ml) 
Total homocysteine (nmol/L) 
Vitamin B6 (nmol/L) 
Vitamin B12 (pg/ml) 
 
26.3 ± 2.8 
13.0 
33.3 
14.8 ± 12.8 
19.8 ± 21.4 
125.0 ± 13.1 
77.7 ± 8.4 
 
423 ± 255 
3.4 ± 5.6 
9.0 ± 6.4 
 
211 ± 45 
45.0 ± 12.2 
146 ± 69 
10.2 ± 5.4 
10.9 ± 3.2 
80 ± 74 
455 ±182 
 
25.7 ± 2.9 
11.4 
29.1 
13.0 ± 11.8 
15.9 ± 18.9 
121.4 ± 12.2 
76.4 ± 8.4 
 
427 ± 221 
3.4 ± 6.3 
9.8 ± 7.8 
 
198.8 ± 43.0 
48.3 ± 13.3 
133 ± 68 
10.5 ± 5.0 
10.4 ± 3.8 
88 ± 90 
471 ±272 
1 Values are means ± SD or %, total n=1034.  
2 n=979 minimum, due to missing data 
3 n=546 minimum, due to missing data 
4 n=630 minimum, due to missing data 
5 To convert mg/dL to SI units (mmol/L), multiply by 0.0259. 
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Table 2.2. Genotype frequency of the MTHFR and MTHFD1 polymorphisms in cases 
and controls, Normative Aging Study, 1961-1998. 
  
Polymorphism  Cases (n=505) Matched controls1 
(n=676) 
MTHFR CC 196 (38.8%) 290 (42.9%) 
 CT 226 (44.8%) 300 (44.4%) 
 TT 83 (16.4%) 86 (12.7%) 
    
MTHFD1 GG 141 (27.9%) 175 (25.9%) 
 GA 267 (52.9%) 365 (54.0%) 
 AA 97 (19.2%) 136 (20.1%) 
    
1 Includes disease-free controls and cases who were used as matching controls prior to 
the disease onset.  
 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3. Mean serum levels of total homocysteine and 95% confidence interval 
stratified by MTHFR 677 genotype status and folate tertiles in men in the nested case 
control study, Normative Aging Study, 1961-1998. 
 
  Folate Tertile*   
Genotype  Low Medium High Total 
MTHFR CC 11.5 (10.7-12.2) 9.8 (9.0-10.6) 9.2 (8.5-9.9) 10.2 (9.7-10.7) 
 CT 11.7 (11.1-12.3) 9.8 (9.0-10.6) 9.3 (8.6-10.0) 10.4 (10.0-10.8) 
 TT 14.9 (13.7-16.0) 11.6 (10.3-12.8) 9.3 (7.9-10.7) 11.9 (11.1-12.7) 
 Total 12.7 (12.2-13.2) 10.5 (9.9-11.0) 9.3 (8.7-9.9)  
* Low folate tertile is defined as serum folate <7.5 nmol/L, medium as ≥7.5 and  
≤ 12.7 nmol/L, and high as >12.7 nmol/L)
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Table 2.4. Multivariate conditional logistic models evaluating MTHFD1 1958G→A, MTHFR 677C→T genotypes, and their 
interaction in relation to CVD risk, Normative Aging Study, 1961-1998. 
 
Model1: Crude Covariate-adjusted Covariate and homocysteine 
adjusted 
Model variables: β2 SE     P β SE P β SE P 
MTHFD1 1958G→A (GA/AA vs. GG) -0.33 0.20 0.10 -0.48 0.22 0.03 -0.70 0.32 0.028 
MTHFR 677C→T (CT vs. CC) -0.16 0.23 0.49 -0.27 0.25 0.28 -0.58 0.35 0.10 
MTHFR 677C→T (TT vs. CC) 0.25 0.33 0.44 0.096 0.36 0.79 -0.36 0.49 0.46 
Interaction: 
 MTHFD1 1958 (GA/AA vs. GG) and MTHFR 
 677 (CT vs. CC) 3 
0.35 0.27 0.19 0.48 0.29 0.095 0.78 0.41 0.058 
 MTHFD1 1958 (GA/AA vs. GG) and MTHFR 
 677 (TT vs. CC) 3 
0.21 0.38 0.59 0.37 0.41 0.36 0.70 0.56 0.21 
1 Models are crude (unadjusted for covariates), covariate-adjusted (adjusted for body mass index, total cholesterol level, 
triglycerides level, drinking alcohol, smoking status, and pack-years of smoking), and covariate and homocysteine adjusted 
(adjusted for covariate list and homocysteine). 
2Values are β=regression coefficient, SE=standard error of regression coefficient, and P=P value. 
3 Likelihood-ratio test of the statistical significance of the set of two interaction terms:  
Unadjusted model: χ2 = 1.691; P=0.4293; Covariate adjusted model: χ2 = 2.827; P=0.2432; Covariate and homocysteine-adjusted 
model: χ2 = 3.855; P=0.1455 
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Table 2.5. MTHFD1 1958G→A and  MTHFR 677C→T genotype effect sizes, stratified by the levels of the other genotype, based 
on the estimates provided in Table 2.3, Normative Aging Study, 1961-1998. 
 
 MTHFR effect:  MTHFD1 subgroup 
  MTHFD1 GG 
 
MTHFD1 GA/AA 
 
Covariate-adjusted model*    
 MTHFR CT vs. CC 0.76 (0.46- 1.25) 1.24 (0.92- 1.66) 
 MTHFR TT vs. CC 1.10 (0.55- 2.21) 1.60 (1.06-2.42) 
Covariate + serum 
homocysteine adjusted 
model 
   
 MTHFR CT vs. CC 0.56 (0.28-1.12) 1.22 (0.78- 1.90) 
 MTHFR TT vs. CC 0.70 (0.27- 1.81) 1.41 (0.79- 2.49) 
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gene (MTHFR 677 C→T) and the MTHFD1 gene (MTHFD1 1958 G→A) on the risk 
of cardiovascular disease and on serum homocysteine levels. 
We observed significant independent effects of the MTHFR 677C→T 
genotype and folate deficiency on serum homocysteine levels, as well as a statistically 
significant gene-nutrient interaction. The effect sizes for the interaction of MTHFR 
and folate may be underestimated due to randomly missing data: the strongest effect of 
homozygosity for MTHFR variant T allele on CVD risk was seen in men with missing 
serum folate data (data not shown). Overall, these findings are consistent with 
previous findings on the effect of MTHFR polymorphism on homocysteine levels in 
populations with suboptimal folate nutritional status, indicating the suitability of this 
population for the study of further gene-nutrient and gene-gene interactions in the 
folate metabolic pathway. Folate-replete populations (such as North American 
populations after the institution of folate fortification) show an attenuated relation 
between MTHFR and homocysteine levels1-3. Thus, these data provide an optimal 
population for studying folate metabolism and disease risk.  
MTHFD1 1958 G→A had little or no independent association with CVD, but 
an interaction with the MTHFR 677 C→T genotype was found. The effect of the 
MTHFR genotype was limited to the subgroup of men with the MTHFD1 GA/AA 
genotype: there was a 60% increase in CVD risk in this subgroup, compared to little or 
no increased risk of the MTHFR TT or CT genotype in the subgroup of men with the 
MTHFD1 GG genotype.  The interaction was independent of another polymorphism, 
namely cSHMT 1420 C→T, which has been shown to be important in one-carbon 
metabolism in general and in cardiovascular disease pathology in this population15 . 
The role of the MTHFD1 1958 polymorphism was originally identified in a 
study of neural tube defects5: the allele frequency was not significantly different 
between cases and control in that study. However, the A allele was associated with an 
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elevated risk of developmental and obstetric outcomes in other studies of neural tube 
defects (NTDs), pregnancy loss, and placental abruption4, 6, 7, 9, 10. The MTHFD1 A 
allele was associated with increased risk of NTD (OR 1.5, 95% CI 1.2, 2.0) in a 
family-based study, but no difference was observed in serum folate and homocysteine 
levels between genotype groups4. Similarly, the A allele was associated with an 
increased risk of NTDs in an Italian population (OR 1.1 for AA vs. GG, and 1.7 for AG 
vs. GG)6. These two studies did not investigate gene-gene interactions. In two studies 
on second-trimester pregnancy loss and placental abruption in Ireland, the variant A 
allele increased the risk of the outcome, but the gene-biomarker association was not 
reported9, 10. The effect of the MTHFD1 genotype in both studies was independent of 
MTHFR genotype, but gene-gene interactions were not assessed.  A small study of 
omphalocele found no effect of MTHFD1 genotype21. Three studies investigated the 
association of MTHFD1 genotype with chronic disease outcomes, including colorectal 
cancer11, migraine22, and spontaneous cervical artery dissection12. None of these 
studies reported a relation of the MTHFD1 polymorphism to the clinical outcome, but, 
a statistically significant interactive effect with MTHFR was reported in migraine 
study. Overall, the MTHFD1 A allele, increased risk of some outcomes, particularly in 
homozygotes.  
The MTHFD1 and MTHFR enzymes catalyze sequential steps in the folate 
metabolic network, leading to the hypothesis of interaction between them in relation to 
the risk of CVD.  The three reaction steps catalyzed by MTHFD1 provide the substrate 
for MTHFR, which is responsible for the provision of 5-methylTHF for the 
remethylation of homocysteine to methionine. MTHFD1 or MTHFR variants with 
decreased functional capacity are therefore expected to result in increased 
homocysteine levels and increased cardiovascular disease risk. We have observed that 
the effect of the MTHFR polymorphism is modified by MTHFD1 genotype. Other 
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studies have investigated the relation of MTHFD1 to a variety of outcomes, but most 
have not considered an interaction with MTHFR 677 genotype. Only one prior study 
of migraine reported a differential effect of MTHFR T allele across MTHFD1 
subgroups: the MTHFR T allele was associated with a protective effect in the 
MTHFD1 GG subgroup and with an increased risk in the MTHFD1 GA/AA subgroup: 
subgroup-specific effects were not reported22.    
Folate nutritional status has been shown to be an effect-modifier of the 
MTHFR—homocysteine and MTHFR—CVD relations3. Serum folate concentration as 
a proxy for folate nutritional status was available in a subset of the study population, 
and a significant gene-nutrient interaction was detected in models predicting serum 
homocysteine. The gene-nutrient interaction was not as strong in models with CVD as 
an outcome: the MTHFR—CVD association was strongest in men with missing data 
on serum folate, suggesting that this lack of interaction was mainly due to missing 
data.  
Serum homocysteine is hypothesized to partially or wholly mediate the 
association of the MTHFR and MTHFD1 polymorphisms with CVD risk. If the effect 
of genotype were entirely mediated by homocysteine, then the addition of 
homocysteine to the multiple conditional logistic regression models of CVD would be 
expected to attenuate and/or eliminate the effect of genotype. In these data, the 
addition of serum homocysteine to regression models did not decrease the magnitude 
of the gene—gene interaction coefficients. Indeed, the statistical significance of the 
gene—gene interaction was strengthened in the homocysteine- and covariate-adjusted 
models vs. the covariate-adjusted models (P values of 0.058 and 0.21 vs. 0.095 and 
0.36, respectively: Table 2.4). A limitation is that serum biomarker data were available 
only on a subset of the study population; therefore evaluating the effect of mediation 
by the biomarkers does not include the entire set of cases and matched controls. The 
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strengthening of interaction in homocysteine-adjusted models suggests that the 
observed gene-gene interaction is mediated through homocysteine, but not in the 
expected way.  
While mild hyperhomocysteinemia has been proposed to be a causal factor in 
atherogenesis based on a large body of observational epidemiologic evidence23, 24, this 
view has been challenged by two recent homocysteine-lowering randomized 
controlled trials showing no effect of lowering homocysteine levels through vitamin 
administration on cardiovascular disease risk or recurrence25, 26. Since homocysteine is 
part of a larger metabolic network that provides substrates for many biological 
functions (methylation reactions, nucleotide biosynthesis, provision of folate cofactor 
forms), functional genetic polymorphisms in the genes of the network might exert 
their effect through pathways other than methionine biosynthesis.  
The prospective nature of the NAS cohort is important because it minimizes 
the biases associated with case-control studies of cardiovascular disease. Another 
strength of the study is the availability of serum biomarker data on folate and 
homocysteine. This allowed us to examine the role of effect modification by folate and 
effect mediation by homocysteine. However, a potential weakness was the limited 
availability of biomarker data in a subset of the original case-control population. 
Another feature of our study was the consideration of genetic variants on two genes 
that encode sequential enzymes in the folate metabolic network. It is biologically 
plausible to observe gene-gene interaction between two variants that affect functional 
capacity of sequential steps in a biochemical pathway.  
The MTHFD1 1958 G→A is a common polymorphism, minor allele frequency 
is 64%, therefore the observed effect may have important implications at the 
population level. The NAS nested case-control study has a relatively large sample size 
of about 500 cases and 1000 matched controls. This provides adequate power to 
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evaluate independent main effects, with odds ratios between 1.4 (81% power) and 1.5 
(93%). However, the power to evaluate interactions of similar magnitude is restricted 
in the stratified analysis given the cross-tabulation of genotypes (power for OR=1.4 
equals 52% when sample size is reduced in half). Inadequate sample size can explain 
the marginally significant P values for interaction in our study. A study twice as large 
would have adequate power (81%) to evaluate an odds ratio of 1.4 in an interaction 
model.  
In summary, we investigated the role of the MTHFD1 1958G→A and MTHFR 
677C→T polymorphisms in relation to serum homocysteine level and cardiovascular 
disease risk. There is some evidence for a gene-gene interaction such that the effect of 
the MTHFR 677C→T genotype is limited to men with the MHTFD1 variant genotype. 
The observed effects are independent of homocysteine.  This is the first report of the 
relation of the MTHFD1 polymorphism to cardiovascular disease in a cohort study. 
Evaluation of this interaction in future studies on genetic aspects of cardiovascular 
disease is recommended.  
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CHAPTER 3 
 
CYTOPLASMIC SERINE HYDROXYMETHYLTRANSFERASE 
(CSHMT) AND METHYLENE-TETRAHYDROFOLATE REDUCTASE 
(MTHFR) GENE POLYMORPHISMS AND CORONARY HEART DISEASE 
RISK IN US WOMEN 
 
Abstract 
Genetic variation in folate-regulating enzymes contributes to metabolic and 
nutritional influences on cardiovascular disease. Prior findings in a case-control study 
of men show that genetic variation in the cytoplasmic serine hydroxymethyltransferase 
gene (cSHMT 1420C→T) modifies the effect of MTHFR 677 genotype on CVD risk. 
This study investigates the same question in a cohort of women (the Nurses’ Health 
Study, NHS). The NHS,a cohort study of 121,700 female nurses established in 1976, 
followed participants biennially through mailed questionnaires.  250 cases of 
cardiovascular disease (CVD) occurred among individuals who provided a blood 
sample. Controls were matched to cases on age and smoking status.  The variant allele 
frequency of the cSHMT and MTHFR polymorphisms was 29.8% and 30.9%, 
respectively.  There was little or no main effect of cSHMT 1420C→T TT on the risk of 
CVD (OR= 0.94; 95% CI: 0.5, 1.7) compared to cSHMT 1420C→T CC/CT. There 
was a complete absence of cases with the MTHFR TT/cSHMT TT genotype, therefore 
no estimate could be made for the risk of CVD associated with the MTHFR 677C→T 
polymorphism among women with the cSHMT 1420C→T TT genotype. An 
interaction between the effect of the MTHFR 677C→T CT genotype (vs. CC)  and the 
cSHMT 1420C→T genotype (P=0.09) was evident. The effect of MTHFR 677C→T 
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CT (vs. CC) on CVD risk differed markedly by the cSHMT genotype. There was little 
or no association of the MTHFR 677C→T CT genotype with CVD in the cSHMT 
CC/CT subgroup (OR 1.1, 95% CI 0.8, 1.5), but there was about a 3-fold increased 
risk in the cSHMT TT subgroup (OR 2.7, 95% CI 0.9, 8.8). These data provide a 
partial replication of the MTHFR 677-cSHMT 1420 interaction reported in a prior 
study of men. Lack of cases with the double homozygous genotype is likely due to 
random variation. Evaluation of this interaction in future studies of folate metabolism 
and cardiovascular disease is recommended. 
Introduction 
Cytoplasmic serine hydroxymethyltransferase (cSHMT) is a member of the 
folate-dependent one-carbon metabolic network that reversibly converts serine and 
tetrahydrofolate (THF) to glycine and 5,10-methylenetetrahydrofolate (5,10-
methyleneTHF) 1. The one-carbon group of 5,10-methyleneTHF is used in the 
synthesis of purines or thymidylate or in the remethylation of homocysteine to 
methionine. A common single nucleotide polymorphism (SNP) in the cSHMT gene, 
L474F (or, equivalently, 1420C→T), has been identified and associated with elevated 
plasma and red blood cell folate levels2 . Epidemiologic studies suggest the presence 
of functional biochemical consequences given associations of this SNP with metabolic 
disruption and disease risk, including altered homocysteine concentrations3, decreased 
risk of leukemia4, and decreased risk of malignant lymphoma5. A recent study 
reported a gene-gene interaction between cSHMT 1420C→T and MTHFR 677C→T 
polymorphisms in relation to CVD risk6, such that the effect of the MTHFR genotype 
was stronger in the presence of the variant cSHMT allele.  
MTHFR and cSHMT catalyze two sequential reactions in the folate metabolic 
network: thus, the reported gene-gene interaction between cSHMT 1420C→T and 
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MTHFR 677C→T polymorphisms in relation to CVD risk is biologically plausible. 
However, such associations in epidemiologic studies may be explained by 
methodologic and/or biologic factors, and continued investigation of this gene-gene 
interaction in new populations is warranted. The first report of an interaction between 
cSHMT 1420C→T and MTHFR 677C→T in relation to CVD risk was based on males 
only7, making investigation of the interaction in females a high priority. The study 
reported herein investigates the main and interactive effects of cSHMT 1420C→T and 
MTHFR 677C→T in a nested case-control study of coronary heart disease within a 
cohort of US women. The association of genotype with serum homocysteine level, a 
marker of folate-dependent remethylation, was also explored in light of the potential 
mediation of this relation through homocysteine elevation. 
 
Methods 
Study design and population 
A nested case-control study was conducted within the Nurses’ Health Study 
(NHS), a prospective cohort study of 121,700 female registered nurses in the United 
States. The cohort study was initiated in 1976, when the participants were aged 30-
558. Study participants completed detailed, self-reported questionnaires assessing 
dietary intake, lifestyle factors, and medical history. Every two years, follow-up 
questionnaires were mailed to update information on potential disease risk factors and 
newly-diagnosed disease. The details of selection of cases and controls for this study 
have been published elsewhere 9: cases and controls were selected from among the 
subset of the cohort (32,826 of the initial 121,700) who gave a blood sample. In brief, 
248 incident cases of nonfatal MI and fatal CVD between 1990 and 1998 occurred in 
women who had provided a blood sample and were free of CVD or cancer at blood 
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draw: these 248 cases comprised about one fourth of all cases that occurred in women 
initially free of CVD in the full cohort. Nonfatal MI was confirmed by study 
physicians blinded to participants’ exposure status using World Health Organization 
criteria10. Fatal CVD was confirmed by hospital records, autopsy report, or death 
certificate, if CVD was the most plausible cause, and if evidence of previous CVD 
was available11. Two matched controls for each case were randomly selected from 
participants free of coronary heart disease at the time the case was diagnosed. Control 
identification used risk-set sampling12, 13 and matched on age, smoking, month of 
blood draw, fasting status, and reports of any problems with blood drawing.  
The study was approved by the Institutional Review Board of the Brigham and 
Women's Hospital, the Harvard School of Public Health Human Subjects Committee 
Review Board, and the Cornell University Committee on Human Subjects. 
Measurement of biochemical and genotype variables 
Between 1989 and 1990, a blood sample was requested from all participants of 
the NHS cohort through mail, and was provided by 32,826 women. Participants who 
provided blood samples had a similar distribution of cardiovascular risk factors 
compared to those who did not provide blood. Participants received a blood collection 
kit and collected whole blood samples in liquid sodium heparin blood tubes. The 
samples were returned in an enclosed ice pack via overnight mail and were 
centrifuged, separated, and aliquoted for storage in liquid nitrogen freezers (−130 °C). 
Plasma folate was measured using a radioimmunoassay kit (Bio-Rad, Richmond, CA), 
and homocysteine was measured by using HPLC at the Jean Mayer US Department of 
Agriculture Human Nutrition Research Center on Aging (Tufts University, Boston, 
MA). Laboratory personnel conducting the assays were blinded to case-control status. 
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The intra-assay coefficient of variation for folate and homocysteine was 6.8% and 
2.9%, respectively14. 
DNA was extracted from buffy coat fractions using the QIAmp Blood Kit 
(Qiagen, Chatsworth, CA), and cSHMT 1420C→T and MTHFR 677C→T genotypes 
were assessed  using the ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems, Foster City, CA). Primers and probes are available from the authors on 
request. Replicate quality control samples were included and genotyped with 100% 
concordance. Matched case-control sets were incomplete in a few instances due to 
genotype failures, thus, genotype data were available for 720 women (240 cases and 
480 controls). 
Statistical analysis 
The Student's t-test and Wilcoxon's rank sum test were used for comparisons of 
continuous and nonparametric variables, respectively. The chi-square test was used to 
compare proportions between cases and controls and between genotype subgroups, 
and to assess Hardy–Weinberg equilibrium. Conditional logistic regression models 
were used to estimate relative risks. A genetic model categorizing genotype subgroups 
for inclusion in the conditional logistic regression model was determined based on 
previous findings and confirmed as appropriate in this population (additive model for 
MTHFR 677C→T and recessive model for cSHMT 1420 C→T)15. All analyses were 
performed using SAS v8.2 (SAS Institute, Cary, NC). 
Results 
 
Table 3.1 presents the baseline characteristics of women by case-control status. 
The matching factors were age, smoking, and sample collection conditions. Cases had 
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higher body-mass index and a greater proportion with family history of myocardial 
infarction compared to controls (46% vs. 29%, P<.0001). Cases were more likely to 
have a history of hypertension (57% vs. 29%, P < .0001) and a higher total cholesterol 
(P = .0010). Alcohol intake was greater in controls compared to cases (P =.0359) and 
moderate alcohol intake (between 0.1 and 30 g/day) was reported more often in 
controls (P = .0040). There was little or no difference in folate-related biomarkers 
between cases and controls, with the exception of vitamin B6 (mean in controls 
greater than in cases; P = 0.045). 
The genotype frequencies of two polymorphisms are shown by case-control 
status. The frequency of the cSHMT 1420 C→T TT genotype was 7.7% in cases and 
8.1% in controls. The prevalence of MTHFR 677 C→T TT was 10% in cases and 
9.6% in controls. The joint distribution of the two polymorphisms revealed a complete 
absence of double homozygotes (cSHMT TT/MTHFR TT) in the case group (Table 
3.2), limiting further analyses.  
The cSHMT 1420C→T polymorphism (TT vs. CC/CT) was not associated with 
coronary heart disease in the unadjusted regression model (OR 0.94, 95% CI 0.5, 1.7) 
or in covariate-adjusted models (OR 0.98, 95% CI 0.4, 2.3). The addition of MTHFR 
677C→T genotype to this model had little or no effect on regression coefficients for 
cSHMT genotype in crude or adjusted models. The MTHFR 677C→T genotype had 
little or no association with coronary heart disease in these data (MTHFR CT vs. CC: 
OR 1.15, 95% CI 0.8, 1.6 and MTHFR TT vs. CC: OR 1.13, 95% CI 0.7, 1.9). 
The conditional logistic regression model testing the MTHFR by cSHMT 
interaction could not estimate the risk of CVD associated with the MTHFR 677C→T 
polymorphism among women with the cSHMT 1420C→T TT genotype due to the 
absence of double homozygote cases (Table 3.2). Thus, the evaluation of gene-gene 
interaction was limited to evaluating the effect of the MTHFR 677C→T CT genotype 
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(vs. CC) across levels of the cSHMT 1420C→T genotype. There was evidence for an 
interaction in the crude conditional logistic regression model (P = 0.13 for the 
interaction coefficient) (Table 3.3). The statistical significance of the interaction 
coefficient was strengthened when homocysteine was adjusted in the model (P=0.09; 
Table 3.3). Further adjustment for a comprehensive set of covariates made little or no 
difference to the effect estimates for genotype, but resulted in a large decrease in 
sample size and thus are not presented herein (n decreased from 747 to 564). Since the 
drop in sample size produced a different starting point for the analysis and there is no 
difference in covariates by genotype groups (data not shown), analyses focused on the 
crude and homocysteine-adjusted models.  
To estimate the effect of the MTHFR variant allele in subgroups of women 
according to their cSHMT genotype, the coefficient estimates from Table 3.4 were 
used to calculate effect estimates and associated 95% confidence intervals. The effect 
of MTHFR 677C→T CT (vs. CC) on CVD risk differed markedly by the cSHMT 
genotype (Table 3.4). There was little or no association of the MTHFR 677C→T CT 
(vs. CC) genotype with CVD in the cSHMT CC/CT subgroup (OR 1.1, 95% CI 0.8, 
1.5), and almost a 3-fold increased risk in the cSHMT TT subgroup (OR 2.7, 95% CI 
0.9, 8.8) (Table 3.4). In models adjusted further for plasma total homocysteine, the 
corresponding odds ratio estimates for the effect of MTHFR 677C→T CT (vs. CC) on 
CVD risk were 1.05 (in cSHMT CC/CT subgroup; 95% CI 0.8, 1.5) and 3.3 (in 
cSHMT TT subgroup; 95% CI 0.9, 11.7) (Table 3.4).  
The average concentration of homocysteine, a marker of folate-dependent 
remethylation, was not statistically significantly different across genotype groups 
(Table 3.5). However, two patterns are worthy of mention. Lower plasma folate levels 
were observed with increasing number of MTHFR variant T alleles in women with the  
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Table 3.1. General baseline characteristics of women with incident coronary heart 
disease (cases) and matched* controls from a nested case-control study within the 
Nurses’ Health Study cohort. 
Cases 
(N = 249) 
Controls 
(N = 498) 
  
Covariatesa Mean ± SD Mean ± SD P value  
Age (yrs) 60.4 ± 6.5  60.3 ± 6.5  .8107 
BMI  25.5 ± 5.5  23.8 ± 3.6 <.0001 
Family History of MI (%) 45.8  29.4  <.0001 
Hypertension (%)  57.4 29.3 <.0001 
Cholesterol (mg/dL) 235.9 ± 40.2 225.5 ± 40.0 .0010 
HDL-cholesterol (mg/dl) 51.7 ± 14.6 60.3 ± 17.5 <0.001 
LDL-cholesterol (mg/dl) 143  ± 34.5 132 ± 36.4 <0.001 
Post-Menopausal Hormone 
Use at blood draw (%) 
30.5 36.4 .1143 
Smoking Status (current 
smokers) (%) 
45.8 39.0 .0739 
Aspirin Usage (% users) 44.1 41.3 .5051 
Alcohol Intake (gms/day) 4.5 ± 9.6 6.2 ± 10.7 .0359 
  0.1 ≤ 30 g/day (%) 49.8 60.8 .0040 
  ≥ 30 g/day (%) 4.4 4.2 .8983 
Physical Activity (Mets/week) 13.9 ± 15.7 14.9 ± 17.0 .4256 
Caloric Intake (kcal/day) 1746.4 ± 511.5 1770.2 ± 522.0 .5648 
Plasma Folate (ng/mL) 8.8 ±  6.4 8.2 ± 7.2 .2646 
Homocysteine (nmol/mL) 11.3 ± 3.8 10.9 ± 5.8 .2360 
RBC Folate (ng/g Hb) 1201.8 ± 352.7 1208.7 ± 366.4 .8073 
B6 (pmol/ml) 58.05 ± 75.9 73.40 ± 131.7 .0451 
B12 (pg/ml) 446.2 ± 175.2 450.1± 184.7 .7816 
* Matching criteria were age, smoking, date of blood draw, fasting status at blood 
draw, and problems with blood draw.  
a The majority of covariates were measured in a subset of cases and controls, thus 
reducing sample sizes as follows: BMI (n= 739), cholesterol (n=737), HDL-
cholesterol (n=737), LDL-cholesterol (n=718), caloric intake (n= 710), alcohol intake 
(n= 710), RBC folate (n= 740), Plasma folate (n= 737), B6 level (n=740 ), B12 level 
(n= 737), and homocysteine level (n= 738). 
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Table 3.2. The joint distribution of MTHFR 677C→T and cSHMT 1420C→T 
genotypes by cases-control status in the Nurses’ Health Study. 
 
Cases (n= 249)  Controls (n= 498)  Polymorphism 
n CC/CT 
(%) 
TT 
(%) 
n CC/CT 
(%) 
TT 
(%) 
cSHMT 1420C→T 234 92.3 7.7 467 91.9 8.1 
MTHFR 677C→T 240 90 10 481 90.4 9.6 
cSHMT 1420C→T 
stratified by: 
      
MTHFR 677 CC 100 94.0 6.0 220 91.8 8.2 
MTHFR 677 CT 106 88.7 11.3 193 91.7 8.3 
MTHFR 677 TT 23 100 0 45 91.1 8.9 
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Table 3.3. Multivariate conditional logistic regression models of the relation of 
MTHFR 677C→T and cSHMT 1420C→T genotypes, and their interaction, to 
coronary heart disease risk, Nurses’ Health Study. 
 
 Crude1 model Homocysteine-
adjusted2 model  
Model variables: β SE P β SE P 
cSHMT 1420C→T  
(TT vs. CT/CC) 
-0.58 0.48 0.22 -0.84 0.53 0.11 
MTHFR 677C→T  
(CT vs. CC) 
0.06 0.17 0.69 0.048 0.17 0.78 
MTHFR 677C→T  
(TT vs. CC) 
0.13 0.28 0.64 0.08 0.28 0.77 
Gene-Gene Interaction3  
cSHMT 1420 (TT vs. CT/CC) 
and MTHFR 677 (CT vs. CC) 
0.94 0.62 0.13 1.15 0.67 0.09 
1 Values are regression coefficient, SE of regression coefficient and P value from 
crude (unadjusted) models; N=747 in crude model 
2 Model adjusted for homocysteine only, N=738  
3 Due to lack of double homozygous variants among the cases, the second interaction 
term cannot be estimated in the model. 
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Table 3.4. Model-based estimates (95% confidence interval) of MTHFR 677C→T and 
cSHMT 1420C→T genotype effects, Nurses’ Health Study. 
 
  Genotype strata  
 
Model 
 
Effect 
cSHMT 1420C→T 
CC/CT 
cSHMT 1420C→T 
TT 
Crude model1    
 MTHFR CT vs. CC 1.07 (0.76-1.5) 2.7 (0.85-8.8) 
 MTHFR TT vs. CC na* na 
Homocysteine-
adjusted model2  
   
 MTHFR CT vs. CC 1.05 (0.75-1.47) 3.3 (0.93-11.7) 
 MTHFR TT vs. CC na na 
1 All cases and controls have data, N=747 
*There is no model estimate for this interaction due to zero cases in double 
homozygote group 
2 Cases and controls with homocysteine data, N=738 
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Table 3.5. Folate-related biomarkers and dietary folate intake in genotype subgroups in cases and controls, Nurses Health Study 
nested case-control study.  
 MTHFR 677 CC MTHFR 677 CT MTHFR 677 TT 
cSHMT 1420 CC/CT n = 293 n = 270 n = 64 
Plasma Hhomocysteine 
(nmol/mL) 
11.1 ± 4.2  10.8 ± 3.6  11.0 ± 3.0  
Plasma Folate (ng/mL) 8.8 ± 7.6  8.1 ± 6.7  6.8 ± 5.1  
RBC Folate (ng/g Hb) 1213.0 ± 382.2 1194.4 ± 338.8 1183.9 ± 319.5 
Dietary Folate (w Supp)mcg 429.3 ± 225.2  420.1 ± 242.7  448.6 ± 235.5  
Dietary Folate (w/out 
Supp)mcg 
301.9 ± 93.3  303.1 ± 91.4  315.0 ± 107.4  
Plasma B6 (pmol/ml) 69.5 ± 94.9 60.9 ± 67.8 99.7 ± 290.1 
Plasma B12 (pg/ml) 441.5 ± 171.4 455.2 ± 188.4 450.5 ± 178.1 
    
cSHMT 1420 TT n = 24 n = 28 n = 4 
Homocysteine (nmol/mL) 13.5 ± 20.7  12.0 ± 4.9  10.4 ± 4.3 
Plasma Folate (ng/mL) 9.8 ± 8.8  9.2 ± 6.6  11.8 ± 9.5  
Mean RBC Folate (ng/g Hb) 1343.2 ± 388.9 1167.8 ± 362.4 1411.1 ± 729.8 
Dietary Folate (w Supp) 453.9 ± 256.2  447.8 ± 248.4  585.5 ± 471.8  
Dietary Folate (w/out Supp) 292.3 ± 111.6  285.8 ± 71.1 384.3 ± 228.1  
Plasma B6 (pmol/ml) 66.4 ± 57.3 54.4 ± 93.6 55.9 ± 28.3 
Plasma B12 (pg/ml) 469.5 ± 223.8 474.4 ± 228.5 520.1 ± 265 
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cSHMT CC/CT genotypes (8.8 in MTHFR CC, 8.1 in MTHFR CT, and 6.8 in MTHFR 
TT women, respectively. In addition, the average homocysteine concentration of 
women with the MTHFR CT/ cSHMT TT genotype was 12.0 compared to 10.8 among 
women with the MTHFR CT/ cSHMT CC/CT genotype.  
 
Discussion 
We studied the association of two genetic polymorphisms in the folate 
metabolic network (MTHFR 677C→T and cSHMT 1420C→T) with cardiovascular 
disease in a nested case-control study within the Nurses’ Health Study cohort. There 
was little or no independent association of the cSHMT polymorphism with coronary 
heart disease risk in crude or adjusted models, and similarly little association of the 
MTHFR 677C→T genotype with disease risk. There was evidence of an interaction 
between these genes such that the effect of the MTHFR 677C→T genotype was 
limited to the subgroup of women with the TT genotype for the cSHMT 1420C→T 
polymorphism. Thus, the MTHFR 677C→T CT genotype (vs. CC) increased the risk 
of CVD about 3-fold in this subgroup, compared to little or no effect of MTHFR 
677C→T CT genotype among women with the cSHMT 1420C→T CC/CT genotype.  
In the first study to report a gene-gene interaction between the MTHFR 677 
and cSHMT 1420 polymorphisms on CVD16, the increased risk of CVD associated 
with MTHFR 677C→T CT and TT genotypes was of greater magnitude in men with 
the cSHMT 1420C→T TT genotype. The effect size in this study of women is 
somewhat lower in magnitude compared to the report in men. In the Normative Aging 
Study16 the MTHFR 677C→T CT genotype (vs. CC) was associated with a 3.6-fold 
increased risk of CVD (95% CI 1.7, 7.8) among men with the cSHMT 1420C→T TT 
genotype. The smaller effect size reported herein (about a 3-fold increased risk) may 
relate to the phenomenon of “winner’s curse”, which suggests that reported magnitude 
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of a genotype-phenotype association is usually overestimated in the first published 
report of that association17. The complete absence of double homozygote cases 
(MTHFR 677C→T TT and cSHMT 1420C→T TT) in the present study precluded a 
full replication of the gene-gene interaction. The lack of double homozygote cases 
may be explained by a severely increased risk of CVD and ensuing premature 
mortality in the double homozygotes, a highly unlikely scenario given the observed 
effect sizes, or this may be due to a random phenomenon resulting from chance. The 
latter explanation is considered more likely given that blood is collected on less than 
25% of all cohort members, and given that less than 25% of all incident cases 
comprise the studied cases. The observation of a gene-gene interaction in the same 
direction as observed by Lim et al (2005) supports the inference that this interaction 
has a causal role and is not due to a false positive finding. The true size of the effect 
remains to be estimated as further findings accrue. 
Cytoplasmic serine hydroxymethyltransferase (cSHMT) is a key enzyme of the 
folate metabolic network, affecting the intracellular homeostasis among folate cofactor 
forms18. cSHMT reversibly converts serine and tetrahydrofolate (THF) to glycine and 
5,10-methylenetetrahydrofolate (5,10-methyleneTHF), which is, in turn, used in the 
synthesis of purines or thymidylate or in the remethylation of homocysteine. The 
single nucleotide polymorphism (SNP) in the cSHMT gene is a C to T substitution at 
nucleotide 1420, resulting in the amino acid substitution of leucine to phenylalanine at 
position 474 of the protein19. Screening of the coding and regulatory regions of the 
cSHMT gene yielded only 2 other variants: cSHMT 1181G→A, an extremely rare 
variant20 , and an E to Q substitution at amino acid position 340. The functional 
biochemical consequences of cSHMT 1420 C→T variant are under investigation. The 
polymorphism is distant from the enzyme’s active site: results from molecular 
modeling demonstrate that the 1420C→T polymorphism is located on the exterior of 
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the protein on a side chain that faces the bulk solvent (unpublished data, Oppenheim, 
Szebenyi, and Stover, Cornell University). Further evidence supports the role of the 
cSHMT polymorphism in sumoylation of intracellular proteins and regulation of 
nuclear transport (Stover P, personal communication). In a recent study, site-directed 
mutagenesis of the human enzyme expressed in E. coli showed that the polymorphism 
is associated with lower affinity for the pentaglutamate form of the folate ligand (but 
not for the other forms) and decreased rates of pyridoxal phosphate addition to the 
enzyme. The polymorphism did not affect the stability of SHMT or the rate at which it 
converts 5,10-methenyl tetrahydropteroyl pentaglutamate to 5-formyl 
tetrahydropteroyl pentaglutamate21. The polymorphism has also been shown to inhibit 
thymidylate synthase (TS) and to lead to decreased homocysteine remethylation in 
vitro (Stover P, personal communication). 
Evidence supports an association of the cSHMT 1420C→T genotype with 
altered homocysteine level and disease risk in epidemiologic studies of leukemia and 
neural tube defects22, 23. The cSHMT 1420C→T genotype had a significant effect on 
serum homocysteine level: among mothers of children with NTDs, lower plasma 
homocysteine concentrations were reported in mothers with homozygous variant TT 
genotype (vs. CC)24. This effect was not observed in children who were affected by 
NTD, and these effects were not stratified by MTHFR genotype. In a study of adult 
acute lymphocytic leukemia, persons with cSHMT 1420C→T CT genotype had a 2.1-
fold decrease in acute lymphocytic leukemia risk (OR  0.48; 95% CI 0.25, 0.91), 
whereas those with TT genotype had a 3.3-fold reduction in risk (OR 0.31; 95% CI 
0.10, 0.90)23. 
The observed interaction between the cSHMT and MHTFR genotypes is 
biologically plausible because the two enzymes catalyze sequential steps in the folate 
metabolic network. Three proposed functions of cSHMT based on isotope tracer 
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studies are preferential supply of 1-carbon units to thymidylate biosynthesis; glycine-
dependent serine synthesis, leading to depletion of 5,10-methyleneTHF for S-adenosyl 
methionine synthesis; and sequesteration of 5-methyltetrahydrofolate (5-methylTHF), 
leading to a decrease in S-adenosyl methionine synthesis25. Since 5,10-methyleneTHF 
is the substrate for the MTHFR enzyme, alterations in the substrate’s level due to 
functional consequences of the genetic variant in cSHMT gene could affect the 
availability of the substrate for MTHFR action, and hence affect the supply of 5-
methylTHF, and ultimately the homocysteine remethylation reaction. Alteration of 
homocysteine level is one of the proposed mechanisms through which genotypic 
variant in genes of the folate metabolic network might exert their effect. The above-
mentioned NTD study22 provides some evidence for the increased turnover of 
homocysteine in mothers with the variant T allele, but in our study there is no 
evidence for such an effect. We observed that the MTHFR-cSHMT interaction effect 
size is not decreased by including homocysteine level in the model. On the other hand, 
inclusion of homocysteine strengthens the interaction effect size, pointing to a 
different role for homocysteine than traditionally hypothesized.  
 The prospective design of the Nurses’ Health Study cohort is important in 
minimizing the biases associated with case-control studies of coronary heart disease. 
The availability of serum biomarker data on folate and homocysteine prior to 
diagnosis of disease is a strength of the study. The unexpected problem of a complete 
absence of CVD cases with the double homozygous genotype is attributed to the 
random process of sampling subjects and not expected to be related to any specific 
aspect of the study design.  
In summary, this study of women partially confirms a prior report of a gene-
gene interaction between cSHMT 1420C T and MTHFR 677C T polymorphisms in 
men. The cSHMT genotype was not independently associated with CVD risk, but it 
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modified the effect of MTHFR genotype on disease risk. The observed interaction was 
not mediated by serum homocysteine levels. Additional studies are needed to replicate 
this finding and evaluate the role of other functional genetic variants of the folate 
metabolic network.  
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CHAPTER 4 
 
METHIONINE SYNTHASE 2756A→G AND 
METHYLENETETRAHYDROFOLATE REDUCTASE 677C→T AND 1298A→C 
GENETIC POLYMORPHISMS AND CARDIOVASCULAR DISEASE RISK IN 
THE NORMATIVE AGING STUDY 
 
Abstract 
Genetic variation in the folate-regulating enzymes may reveal important clues 
to aid in understanding metabolic and nutritional influences on cardiovascular disease 
(CVD). Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase 
(MTR) catalyze sequential steps in folate-mediated remethylation of homocysteine to 
methionine, thus we hypothesized that variant alleles of these two genes would 
interact to affect CVD risk. This study investigated the association between three 
single nucleotide polymorphisms (SNPs) in these 2 genes (MTHFR 677C→T, MTHFR 
1298A→C, and MTR 2756A→G) and the risk of CVD. Incident cases of CVD 
(n=507) were identified in the longitudinal Normative Aging Study, and two controls 
were selected by matched incidence density sampling. In the simultaneous model, 
considering all SNPs without interactions, only MTHFR 677C→T was associated with 
CVD risk (MTHFR  677C→T TT vs. CC : odds ratio (OR) 1.4; 95% confidence 
interval (CI) 1.0, 2.0). Models including all possible gene-gene interactions revealed a 
statistically significant interaction between MTHFR 1298A→C and MTR 2756A→G 
(P=0.02): the effect of MTHFR on CVD risk was in opposite directions, depending on 
the MTR genotype. The MTR 2756A→G AA genotype(vs. AG/GG) was associated 
with a 50% decrease in the risk of CVD (95% CI 0.23, 1.06) in men with the ΜΤΗFR 
1298A→C CC genotype. In men with the MTHFR 1298A→C AA/AC genotype, the 
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MTR AA genotype increased the risk of CVD (OR 1.30; 95% CI 1.001, 1.69). The 
observed gene-gene interaction was not mediated by homocysteine: inclusion of serum 
homocysteine concentration in the model strengthened the interaction. Evaluation of 
this interaction and similar interactions of sequential steps in the folate metabolic 
network is recommended in future studies of cardiovascular disease.  
 
Introduction 
Genetic variability in genes involved in folate metabolism might affect the 
cardiovascular risk of individuals by altering serum homocysteine concentrations, by 
affecting the composition of folate cofactor pools in endothelial and red blood cells, 
and/or by influencing serum folate levels. The association between variation in some 
of the folate metabolism genes and cardiovascular disease (CVD) has been extensively 
studied and biologic mechanisms underlying these associations have been posited: a 
well-studied case in point is the methylenetetrahydrofolate reductase gene (MTHFR)1. 
Other genes are less well-studied, including the methionine synthase (MTR) gene, 
which has only recently been evaluated in the relation to CVD risk.  One of the main 
pathways for the catabolism of homocysteine, a metabolic intermediate proposed to 
increase the risk of CVD2, is its remethylation, which is dependent on two enzymes. 
Methionine synthase (MTR) is a vitamin B12-dependent enzyme which catalyzes the 
remethylation of homocysteine to methionine. During the remethylation process, MTR 
uses a methyl group, 5-methyltetrahydrofolate (5-methylTHF) provided through the 
action of MTHFR. Since remethylation of homocysteine is dependent on the action of 
MTR (as the catalyzing enzyme) and MTHFR (as the substrate-providing enzyme), 
common genetic polymorphisms in genes encoding these enzymes may cause 
elevations in serum homocysteine concentration and/or other consequences of altered 
folate metabolism leading to an altered risk of clinical consequences. 
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MTHFR catalyzes the conversion of 5,10-methyleneTHF to 5-methylTHF: 5-
methylTHF is the major folate derivative in plasma and provides the methyl group for 
remethylation of homocysteine3, 4. A thermolabile form of MTHFR has been found, 
which exhibits reduced activity and is caused by a common C677T polymorphism of 
the MTHFR gene5, 6. In many studies, the MTHFR 677C→T TT genotype is associated 
with increased plasma homocysteine levels and increased cardiovascular risk, 
especially in subjects with low serum folate levels 7-9. A second common 
polymorphism was reported in exon 7 of the MTHFR gene, a nucleotide 1298A→C 
substitution that leads to a glutamate-to-alanine exchange in the amino acid sequence, 
and also causes reduced MTHFR enzyme activity 10, 11. 
A common polymorphism has been identified in the methionine synthase 
(MTR) gene, an A to G transition at nucleotide 2756 (2756A → G) in the open reading 
frame of the gene resulting in the substitution of a glycine (G) for aspartic acid (D) at 
codon 919 (D919G), a potentially functional site of the protein 12. Only a handful of 
epidemiologic studies, limited by sample size or cross-sectional design, have 
investigated the effect of this polymorphism on homocysteine levels or cardiovascular 
disease risk. Mixed findings include reports of an increase 13, decrease 14-16, or no 
effect on risk 17-20. 
 Evaluating the functional effect of genetic variation in genes contributing to 
linked steps in a metabolic network may lead to the discovery of more robust 
associations between genetic variation and clinical consequences. This approach is 
likely to be far more informative than focusing on single SNPs, but is hampered by 
studies with a small sample size, which have limited statistical power to reliably 
evaluate gene-gene interactions. The objective of this study is to examine the effects 
of three single nucleotide polymorphisms in the MTHFR and MTR genes, and their 
interaction, in relation to the risk of cardiovascular disease.  
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Methods 
 
Study Population 
A nested case-control study was carried out within the prospective Normative 
Aging Study (NAS) cohort. The NAS was established by the Veterans’ Administration 
in 1961 from a pool of several thousand volunteers in the Boston vicinity21. Two 
thousand two hundred eighty community-dwelling men aged 21-81 (mean 42 years at 
study entry) were selected based on health criteria. Men with past or current chronic 
conditions, including coronary heart disease, hypertension, diabetes, cancer, peptic 
ulcer, gout, asthma, chronic bronchitis, and chronic sinusitis, were ineligible. Since 
their enrollment in 1961-1968, participants have undergone comprehensive clinical 
examinations at 3- to 5-year intervals. The response rate was greater than 90% for 
mailed questionnaires, including food frequency questionnaires, which supplemented 
on-site examination. As of June 1998, 543 participants (24%) were deceased and 
about 1600 men (70%) remained under active observation with a mean age of 70 
years. The rate of continued participation of NAS men over the follow-up period was 
excellent, with less than 1% annual attrition for all causes.  
From the beginning of the study through 1998, 749 incident cases of 
cardiovascular disease (CVD) occurred. Cases included incident coronary heart 
disease (CHD) and stroke that occurred between November 1961 and December 1998. 
Possible occurrences of CHD, including angina pectoris and nonfatal myocardial 
infarction (MI), were evaluated based on medical records and physician 
examination22. Angina was defined according to Framingham Heart Study criteria as 
recurrent chest discomfort lasting up to 15 minutes distinctly related to exertion or 
excitement that was relieved by rest or nitroglycerin23. Nonfatal MI was diagnosed 
only when documented by unequivocal electrocardiographic changes together with 
chest discomfort consistent with MI. Possible occurrences of stroke were identified by 
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report of a neurological deficit of sudden or rapid onset that persisted for 24 hours or 
longer and confirmed by neurologists who reviewed individual medical records24. 
CHD or stroke mortality was confirmed by death certificates, which were coded 
according to the eighth revision of the International Classification of Diseases25. 
About six percent of cases had only stroke. DNA was available only for more recent 
cases, thus 535 incident CVD cases were studied. The cases without DNA were older 
at study entry, and had slightly higher systolic blood pressure and greater cumulative 
smoking exposure. 
A total of 1,048 matched controls were selected from the cohort by risk set 
sampling. The controls were matched to each case by age at onset and birth period (in 
five-year intervals) of the case. By this approach, as each case occurred, all other 
cohort members at risk (including cases that occurred at later times), under active 
follow-up, with the same matching conditions, and with DNA available formed a risk 
set for the incident case. Two men from the risk set were randomly chosen as matched 
controls. Therefore, cases were eligible to serve as a control in the time period before 
they were diagnosed, and some individuals, both cases and non-cases, served as a 
control for more than one case26. As a result, the final list of distinct individuals 
selected for the nested case-control study included 535 cases and 547 non-cases, with 
a maximum of 2 controls matched to each case. The study was approved by the 
Brigham and Women’s Hospital Human Subjects committee, the Veterans’ 
Administration R & D committee, and the Cornell University Committee on Human 
Subjects. 
Data Collection: Covariates 
Extensive data were collected on all participants, including physical 
examination data, lifestyle factors and blood analyses. Beginning in 1987, men 
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completed the Willett semi-quantitative food frequency questionnaire (FFQ) on 
dietary intake in the past year. The questionnaire was mailed to participants and 
returned during a scheduled examination.  Estimations of dietary intake, including B 
vitamins, methionine, coffee and alcohol, were derived from the frequency and dosage 
information on the FFQ using software developed by the Nurses’ Health Study 27. At 
least one FFQ measurement was available prior to the date of diagnosis for about half 
of the CVD cases (246 out of 535). For the non-cases, 307 out of 547 had at least one 
FFQ measurement. Certain blood analyses were started after the study baseline as 
well, including serum HDL cholesterol, which was measured beginning in 1981. The 
majority of cases and controls had HDL data before the CVD diagnosis of the case.  
Data Collection: Genotyping Methods 
In 1999, DNA was extracted from stored frozen buffy coat of 7 cc whole 
blood, using the Qiamp DNA blood kits (Qiagen, Valencia CA): DNA was 
successfully extracted for 1,584 participants. Genotypes of three polymorphisms 
(MTHFR 677C→T, MTHFR 1298A→C, and MTR 2756A→G) were determined by 
the TaqMan procedure using the allelic discrimination technique (ABI Prism 7900 
Sequence Detection System, Applied Biosystems, Foster City, CA). The DNA 
samples for all men (cases and controls) were plated in random order with a mixture of 
TaqMan Universal PCR Master Mix, primers, and probes. PCR cycling conditions 
consisted of one two-minute cycle at 50°C, one 10-minute cycle at 95°C, followed by 
40 to 46 cycles at 95°C for 15 seconds and at 60°C for one minute. The primers and 
probes for the two MTHFR polymorphisms and the MTR 2756A→G polymorphism 
were created according to standard methods for the TaqMan procedure.  
Statistical Analysis 
Observed genotype frequencies were compared to those expected in Hardy-
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Weinberg equilibrium28 and tested with the chi-squared statistic. Linkage 
disequilibrium among the three polymorphic sites was tested using the Likelihood 
Ratio Test and Fisher’s Exact Test28. Conditional logistic regression analysis (SAS 
PHREG; SAS Institute, Cary, NC) was used to analyze the risk set sampled cases and 
controls29. Men homozygous or heterozygous for the 2756A→G variant of MTR (GG 
and AG) were compared to homozygous (AA) genotypes because it was established 
that there was little or no risk difference between GG and AG subgroups in overall and 
stratified analyses. To test whether the MTR-CVD association varied by other 
polymorphisms and to assess effect modification of the MTR-CVD association by 
other risk factors, product terms were included in the regression model. Effect 
estimates were derived from these models and confirmed in stratified analyses.  
The MTR-CVD association was estimated in unadjusted models and in models 
adjusted for risk factors for CVD. In addition, the MTR-CVD association was 
estimated in the subset of cases and non-cases with dietary data. Once again, further 
models were considered to assess potential confounding and effect modification.  
Results 
The overall distribution of cardiovascular risk factors in the cases compared to 
the controls (Table 4.1) indicates a pattern of greater CVD risk in cases compared to 
controls, as expected. Given the relation of known risk factors to CVD risk, the 
association of genotype with these risk factors was considered carefully. Genotype had 
little or no association with traditional cardiovascular risk factors, except for alcohol 
use: in men with the MTR 2756AÆG AA genotype the prevalence of drinking more 
than 2 drinks a day was greater compared to men with AG/GG genotype (16.8% vs. 
8.6; Table 4.2). The pattern of vitamin intake, as assessed by total dietary intake of 
folate, vitamin B6, and vitamin B12, was similar between cases and controls, and 
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mean serum homocysteine concentration was 0.5 µmol/L higher in cases.  
The observed genotype frequencies are comparable to reported frequencies in 
other studies of Caucasian populations.  All three polymorphisms are in Hardy-
Weinberg equilibrium. We observed statistically significant linkage disequilibrium 
between MTHFR 677C→T and MTHFR 1298A→C, manifesting as lack of double 
homozygotes (complete absence of MTHFR 677 TT/MTHFR 1298 CC combination).  
In multivariate models considering the relation of genotype to CVD risk, 
genotype models were determined based on past literature and on empirical 
considerations. Thus, for MTHFR 677C→T, the additive model (TT vs. CC and CT vs. 
CC) best captures the relation of this genotype to CVD risk. For MTHFR 1298A→C, 
the recessive model (CC vs. AA/AC) was optimal, and for MTR 2756A→G, the 
dominant model (AG/GG vs. AA) was optimal. The optimal coding of polymorphisms 
was based on the effect size for heterozygous and homozygous variants compared to 
homozygous wildtype genotypes, and the associated P values in unadjusted 
conditional logistic regression models.  
In unadjusted conditional logistic regression models with CVD occurrence as 
the outcome, considering each genotype in separate models, both MTHFR 677C→T 
and MTHFR 1298A→C were significantly associated with increased and decreased 
risk of CVD (Table 4.4), respectively. However, the MTHFR 1298 protective effect 
was completely explained by linkage disequilibrium with MTHFR 677, and with both 
polymorphisms in the model the effect of the 1298 polymorphism is attenuated (odds 
ratio changes from 0.69 to 0.74). In the overall multi-SNP model without interactions, 
only MTHFR 677 C→T TT genotype was associated with increased CVD risk (odds 
ratio (OR) 1.4; 95% confidence interval (CI) 1.0, 2.0) (Table 4.5). The MTR 2756 
polymorphism had little or no association with CVD in the single-polymorphism and 
overall models.  
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Table 4.1. Characteristics at study entry of cases and controls, Normative Aging 
Study, 1961-19981. 
 
Variable Cases Matched Controls 
Questionnaire and Physical Exam2 
BMI 
Alcohol intake, usual ≥ 2/day (%) 
Current smokers (%) 
Duration of smoking (years) 
Cumulative smoking (pack-years) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Food Frequency Questionnaire3 
Folate (µg/d) 
Vitamin B6 (mg/d) 
Vitamin B12 (µg/d) 
Serum Biomarkers4 
Total cholesterol (mg/dL)5 
HDL cholesterol (mg/dL) 5 
Triglycerides (mg/dL) 
Folate (ng/ml) 
Total homocysteine (nmol/L) 
Vitamin B6 (nmol/L) 
Vitamin B12 (pg/ml) 
 
26.3 ± 2.8 
13.0 
33.3 
14.8 ± 12.8 
19.8 ± 21.4 
125.0 ± 13.1 
77.7 ± 8.4 
 
423 ± 255 
3.4 ± 5.6 
9.0 ± 6.4 
 
211 ± 45 
45.0 ± 12.2 
146 ± 69 
10.2 ± 5.4 
10.9 ± 3.2 
80 ± 74 
455 ±182 
 
25.7 ± 2.9 
11.4 
29.1 
13.0 ± 11.8 
15.9 ± 18.9 
121.4 ± 12.2 
76.4 ± 8.4 
 
427 ± 221 
3.4 ± 6.3 
9.8 ± 7.8 
 
198.8 ± 43.0 
48.3 ± 13.3 
133 ± 68 
10.5 ± 5.0 
10.4 ± 3.8 
88 ± 90 
471 ±272 
 
1 Values are means±SD or %, total n=1034.  
2 n=979 minimum, due to missing data 
3 n=546 minimum, due to missing data 
4 n=630 minimum, due to missing data 
5 To convert mg/dL to SI units (mmol/L), multiply by 0.0259.  
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Table 4.2. General Characteristics at Study Entry by Genotype: Controls Only, Normative Aging Study, 1961-19981.   
 MTR 2756A→G  MTHFR 677C→T  MTHFR 1298A→C  
 AA (n=349) AG/GG (n=178) CC(n=229)  CT (n= 241)  TT (n= 57)  
AA/AC 
(n=473) 
CC (n=50) 
Questionnaire and Exam2 
BMI 
Drinkers, usual ≥ 2/day (%) 
Current smokers (%) 
Duration of smoking (years) 
Smoking (pack-years) 
Systolic BP (mmHg) 
Diastolic BP (mmHg)  
Dietary intake (FFQ)3 
Folate (µg/d) 
Vitamin B6 (mg/d) 
Vitamin B12 (µg/d) 
Serum Biomarkers4 
Total cholesterol (mg/dL)5 
HDL cholesterol (mg/dL) 5 
Triglycerides (mg/dL) 
Folate (ng/ml) 
Total homocysteine (nmol/L) 
Vitamin B6 (nmol/L) 
Vitamin B12 (pg/ml) 
 
25.7 ± 3.0 
8.6 
38.7 
13.0 ± 12.0 
15.7 ± 19.3 
121 ± 12.1 
76.4 ± 8.6 
 
424 ± 220 
3.48 ± 6.8 
9.5 ± 8.2 
 
198 ± 44 
48.3 ± 12.5 
131 ± 73 
10.6 ± 5.2 
10.5 ± 4.1 
81 ± 77 
481 ± 304 
 
25.8 ± 2.7 
16.8 
30 
13.1 ± 11.3 
16.3 ± 18.1 
121 ± 12.3 
76.3 ± 7.9 
 
434 ± 226 
3.35 ± 5.2 
10.38 ± 6.9 
 
201 ± 41 
48.3 ± 14.8 
137 ± 57 
10.4 ± 4.7 
10.3 ± 2.9 
101 ± 110 
450 ± 192 
 
25.7 ± 3.1 
12.7 
27.2 
13.1 ± 12.1 
16.1 ± 20.1 
122 ± 12.9 
76.3 ± 9.1  
 
439 ± 225 
3.2 ± 4.7 
9.4 ± 5.9 
 
198 ± 42 
48.2 ± 13.6 
127 ± 52 
11.0 ± 5.2 
10.3 ± 3.3 
93 ± 102 
470 ± 201 
 
25.7 ± 2.7 
10 
28.8 
12.4 ± 11.4 
14.9 ± 17.7 
120.6 ± 12 
76.4 ± 8.1 
 
428 ± 225 
3.9 ± 8.0 
10.6 ± 9.6 
 
199 ± 45 
48.5 ± 13.8 
138 ± 81 
10.3 ± 5.0 
10.3 ± 3.4 
87.5 ± 85.8 
460 ± 200 
 
26.1± 2.3 
12.3 
38.2 
15.5 ± 12.1 
19.6 ± 18.3 
120.6 ± 9.9 
76.3 ± 6.5 
 
377 ± 192 
2.26 ± 1.02 
8.2 ± 4.45 
 
200 ± 40 
48.3 ± 9.3 
137 ± 63 
9.7 ± 4.6 
11.4 ± 5.9 
69 ± 42 
520 ± 586 
 
25.8 ± 2.9 
11.3 
28.3 
12.8 ± 11.7 
15.5 ±18 
121 ±11.8 
76.3 ± 8.2 
 
421 ± 213 
3.46 ± 6.6 
9.7 ± 8.0 
 
200 ± 44 
48 ± 13.3 
134 ± 70 
10.5 ± 5.0 
10.4 ± 3.8 
88 ± 91 
471 ± 280 
 
25.6  ± 2.4 
12 
36.7 
15.2 ± 12 
20.2 ± 25.5 
121 ± 15.2 
77 ± 10.2 
 
490 ± 291 
3.3 ± 1.95 
10.9 ± 5.0 
 
198 ± 33 
49.1 ± 13.8 
126 ± 35 
10.75 ± 5.3 
11.1 ± 3.0 
88 ± 79 
467 ± 184 
1 Values are means ± SD or %, total n=1034. 2 n=979 minimum, due to missing data 3 n=546 minimum, due to missing data 
4 n=630 minimum, due to missing data 
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Table 4.3. Genotype frequencies of the MTHFR and MTR polymorphisms in case and 
control groups, Normative Aging Study, 1961-1998. 
 
Polymorphism  Cases (n=505) Matched controls1 (n=679) 
MTHFR 677 CC 196 (38.7) 291 (42.9%) 
 CT 227(44.8%) 301 (44.3%) 
 TT 84 (16.6%) 87 (12.8%) 
    
MTHFR 1298 AA 242 (47.7%) 318 (46.8%) 
 AC 224 (44.2%) 289 (42.6%) 
 CC 41 (8.1%) 72 (10.6%) 
    
MTR 2756 GG 350 (69.2%) 453 (66.7%) 
 GA 138 (27.3%) 200 (29.5%) 
 AA 18 (3.6%) 26 (3.8%) 
1 Includes disease-free controls and cases serving as matching controls prior to the disease 
onset.
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Table 4.4. Univariate and multivariate models of the relation of genotype with CVD risk, 
nested case-control study within the Normative Aging Study Cohort, 1961-1998. 
 
Models n*  Odds Ratio     95% CI 
1. Unadjusted single polymorphism models 
 
a)MTHFR 677 (CT vs. CC) 
   MTHFR 677 (TT vs. CC) 
b)MTHFR 1298 (CC vs. AC/AA) 
c)MTR 2756 (AG/GG vs. AA) 
 
 
 
1514 
 
1514 
1514
 
 
1.13 
1.54 
0.69 
0.89 
 
 
 
0.90, 1.43 
1.11, 2.15 
0.47, 1.00 
0.70, 1.12 
2. Unadjusted simultaneous model, including all 3 
SNPs 
MTHFR 677 (CT vs. CC) 
MTHFR 677 (TT vs. CC) 
MTHFR 1298 (CC vs. AC/AA) 
MTR 2756 (AG/GG vs. AA) 
 
 
1514 
 
 
 
 
1.04 
1.43 
0.74 
0.89 
 
 
0.81, 1.35 
1.02, 2.02 
0.49, 1.11 
0.71, 1.12   
3. Unadjusted simultaneous model, with all gene-
gene interaction 
MTHFR 677 (CT vs. CC) 
MTHFR 677 (TT vs. CC) 
MTHFR 1298 (CC vs. AC/AA) 
MTR 2756 (AG/GG vs. AA) 
MTHFR 677 (CT vs. CC) by MTR 2756 
MTHFR 677 (TT vs. CC) by MTR 2756 
MTHFR 1298 (CC vs AC/AA) by MTR 2756 
 
 
1514 
 
 
 
1.04 
1.35 
0.52 
0.78 
1.04 
1.22 
2.58 
 
 
0.77, 1.41 
0.90, 2.04 
0.31, 0.90 
0.51, 1.17 
0.60, 1.78 
0.59, 2.53 
1.11, 5.98 
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Table 4.5. Multivariate models evaluating MTR 2756A→G, MTHFR 1298A→C genotypes, and their interaction in relation to CVD 
risk while adjusting for cardiovascular risk factor covariates and serum homocysteine levels, Normative Aging Study, 1961-1998 
 
 Crude Covariate-adjusted2 Covariate and homocysteine 
adjusted3 
Model variables: β1 SE     P β2 SE P β3 SE P 
MTR 2756A→G (AG/GG vs. AA) -0.21 0.12 0.096 -0.26 0.13 0.049 -0.30 0.20 0.13 
MTHFR 1298A→C (CC vs. AA/AC) -0.70 0.25 0.005 -0.77 0.27 0.004 -0.77 0.39 0.05 
Interaction, MTR 2756 and MTHFR 1298 0.90 0.40 0.024 0.98 0.42 0.02 1.97 0.66 0.003 
          
Controlling for MTHFR 677C→T and MTR-
MTHFR interaction  
Crude Covariate-adjusted2 Covariate and homocysteine 
adjusted3 
MTR 2756A→G (AG/GG vs. AA) -0.25 0.21 0.23 -0.44 0.23 0.06 -0.43 0.37 0.25 
MTHFR 1298A→C (CC vs.AA/AC) -0.65 0.27 0.02 -0.77 0.29 0.007 -0.73 0.43 0.087 
Interaction, MTR 2756 and MTHFR 1298 0.95 0.43 0.03 1.15 0.46 0.012 2.09 0.74 0.004 
1 Values are regression coefficient, SE of regression coefficient and P value from crude (unadjusted) models. 
2 models adjusted for covariates including body mass index, serum cholesterol and triglyceride levels, drinking more than two drinks 
per day, current smoking, and a cumulative measure of smoking (pack-years). 
3 models adjusted for covariates listed above, and for homocysteine 
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Table 4.6. MTR 2756AÆG genotype effect size, stratified by the levels of MTHFR 
1298A→C genotype, Normative Aging Study, 1961-1998. 
 
  MTHFR 1298 genotype 
  MTHFR 1298A→C 
CC  
MTHFR 1298 A→C  
AA/AC 
Covariate*-adjusted 
model* 
MTR 2756 AA vs. 
AG/GG  
0.49 (0.23-1.06) 1.30 (1.001-1.69) 
    
Covariate + serum 
homocysteine adjusted 
model 
MTR 2756 AA vs. 
AG/GG 
0.19 (0.06-0.65) 1.35 (0.91- 2.0) 
*Covariates include body mass index, serum cholesterol and triglyceride levels, 
drinking more than two drinks per day, current smoking, and a cumulative measure of 
smoking (pack-years).
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Testing of gene-gene interactions revealed a significant interaction between 
MTHFR 1298A→C and MTR 2756A→G (P=0.02). The interaction was unchanged in 
the covariate adjusted model (P=0.02) and was strengthened when both covariates and 
serum homocysteine concentration were added to the model (P=0.003) (Table 4.6). 
The interaction was unchanged when MTHFR 677 polymorphism and its interaction 
with MTR were added to these models (Table 4.6). We investigated the interaction 
between the MTHFR 677 and MTR 2756 polymorphism in the absence of MTHFR 
1298 polymorphism and found no evidence for an interaction (data not shown).  
The effect of MTR 2756A→G genotype depended on the MTHFR 1298A→C 
genotype. In the adjusted models, among men with the MTHFR 1298A→C CC 
genotype, MTR 2756A→G AA (vs. AG/GG) decreased the risk of CVD (OR 0.49; 
95% CI 0.23, 1.06), whereas among men with the MTHFR 1298A→C AA/AC 
genotype, MTR 2756A→G AA increased the risk of CVD (OR 1.30; 95% CI 0.001, 
1.69). Adding serum homocysteine concentration to the covariate-adjusted models 
strengthened the interaction: among men with the MTHFR 1298A→C CC genotype, 
MTR 2756A→G AA (vs. AG/GG) decreased the risk of CVD (OR 0.19; 95% CI 0.06, 
0.65), whereas among men with the MTHFR 1298A→C AA/AC genotype, MTR 
2756A→G AA increased the risk of CVD (OR 1.35; 95% CI 0.91, 2.0). 
 
Discussion 
We studied the association of three genetic polymorphisms in the folate 
metabolic network (MTHFR 677 C→T, MTHFR 1298 A→C, and MTR 2756A→G) 
with cardiovascular disease in a nested case-control study of the Normative Aging 
Study cohort. We investigated the main and interactive effect of a single-nucleotide 
polymorphism in the MTR gene (MTR 2756 A→G) on the risk of cardiovascular 
disease. MTR 2756 A→G had little or no independent association with CVD, but an 
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interaction with the MTHFR 1298 A→C genotype was evident (P=0.02). The effect of 
MTR on CVD risk was in opposite directions depending on the MTHFR genotype: the 
MTR 2756A→G AG/GG (vs. AA) genotype was associated with an increased risk of 
CVD in men with the ΜΤΗFR 1298A→C CC genotype, whereas in men with the 
MTHFR 1298A→C AA/AC genotype, the MTR genotype was associated with a 
decreased risk of CVD. The interaction was independent of another polymorphism, 
namely MTHFR 677 C→T, which has been shown to be important in one-carbon 
metabolism in general and in cardiovascular disease pathology in this population 30. 
The MTR 2756 polymorphism is an A to G transition at nucleotide 2756 
(2756A → G) in the open reading frame of the gene resulting in the substitution of a 
glycine (G) for aspartic acid (D) at codon 919 (D919G) 31.  MTR has been shown to 
be a modular protein with four functional modules 32. The polymorphism is located in 
the activation domain of the protein that is involved in reductive activation. The A 
allele is suggested to decrease the docking of the MTR enzyme and therefore prevent 
the replenishment of the MTR enzyme through the MTR reductase pathway (Patrick 
Stover, Personal communication). Such an effect would lead to increased 
homocysteine level and potentially an increase in CVD risk given hypothesized 
cardiotoxic actions of homocysteine. Another proposed mechanism for the connection 
between changes in MTR activity and homocysteine level is through RBC folate 
increase and changes in type of folate in the RBC. It has been argued that a reduction 
in MTR activity causes an increase in RBC Methyl-THF, a process referred to as 
methyl trapping. This might be accompanied by an elevated homocysteine (if the 
reduction in enzyme activity is severe)33, or a normal homocysteine level (if the 
reduction in enzyme activity is mild).  
We have previously shown significant effects for folate deficiency and for 
MTHFR 677 polymorphism on homocysteine levels (Chapter 2). We have also 
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reported a significant gene-nutrient interaction between folate deficiency and the 
MTHFR 677 polymorphism, an interaction that is consistent with other studies 34. 
Folate-replete populations (such as North American populations after the institution of 
folate fortification) show an attenuated relation between MTHFR and homocysteine 
levels35, 36. Therefore this sample provides an optimal population for studying folate 
metabolism and CVD risk.  
In these data, no interaction was observed between the MTHFR 677 and MTR 
2756 polymorphisms. MTHFR 677 has been one of the most widely studied genetic 
variants in relation to homocysteine and cardiovascular disease, but the observation 
that another genetic variant that is in close proximity to MTHFR 677 shows an 
independent and strong interactive effect is interesting. MTHFR 1298 was discovered 
as a “second” polymorphism on the MTHFR gene 37, and is in linkage disequilibrium 
with the MTHFR 677 polymorphism. It also causes a reduction in the catalytic activity 
of the MTHFR enzyme, though to a lesser extent compared to the MTHFR 677 
polymorphism38. The observed effect of MTHFR 1298 polymorphism in our study is 
not attenuated by including the MTHFR 677 polymorphism and related interaction 
terms to the regression models. This suggests that although MTHFR 677 is a major 
determinant of genetic variation on MTHFR gene, significant residual genetic 
variation may only be captured by including additional markers on this gene. Using 
haplotypes in this setting is the recommended approach, but to construct reliable 
haplotypes from unphased markers, multilocus genotype data from a number of 
closely-linked variants is ideal: these data are unavailable for the present study. 
The MTR and MTHFR enzymes catalyze sequential steps in the folate 
metabolic network, leading to the hypothesis of interaction between them in relation to 
the risk of CVD. MTR is a B12 dependent enzyme that catalyzes the remethylation of 
homocysteine to methionine. The methyl group for this reaction is provided by 5-
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methyl THF, which is a product of the MTHFR enzyme. Given the known effect of 
MTHFR polymorphism on the functionality of the enzyme, it is plausible to 
hypothesize an interaction between these polymorphisms and a potentially functional 
polymorphism in MTR gene. Other studies have investigated the relation of MTR to a 
variety of outcomes, and some evaluated the role of an MTHFR-MTR interaction, but 
none have detected an interaction between these two polymorphisms. The lack of 
similar findings from other studies may be due to small sample size or population-
specific features of the studies. Studies on the effect of MTR polymorphism on 
homocysteine level or cardiovascular disease risk have had mixed results including 
associations with increased risk 39, decreased risk 40-42, or no effect on risk 43-46.  
In a prospective study of US male physicians, Chen et al. found that the MTR 
GG genotype was associated with a non-significant reduction in MI risk (RR 0.51, 
95% CI 0.17, 1.16) compared to individuals with AA genotype 47. The MTR 
polymorphism was associated with decreased homocysteine levels (10.55, 9.87 and 
9.57 nmol/ml for AA, AG and GG genotypes, respectively) only among controls 48. 
Similarly in a study on subjects from the NHLBI Family Heart Study, a weak positive 
association was observed between changes in homocysteine after a methionine load 
and the number of mutant MTR alleles (P trend = 0.04), but this was not significant in 
the overall F test 49. These studies are similar to our study in having a relatively large 
sample size (about 500 cases) and therefore have adequate power to detect an 
association between the variant allele and alterations in homocysteine level of the 
order of magnitude reported herein. Our results are consistent with these findings, and 
other reports that fail to see a significant association between the fasting homocysteine 
concentration and the MTR 2756 polymorphism.  
Serum homocysteine may partly or wholly mediate the relation of the MTHFR 
and MTR polymorphisms with CVD risk. The further addition of serum homocysteine 
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to regression models increased the magnitude of the gene-gene interaction 
coefficients. This is in contrast to the expectation of attenuation of coefficients that 
would be expected if homocysteine mediated the genotype effects. Therefore our 
findings suggest that the observed gene-gene interaction is not mediated through 
homocysteine. The view that mild hyperhomocysteinemia is a causal factor in 
atherogenesis has been challenged by two recent homocysteine-lowering randomized 
controlled trials showing no effect of lowering homocysteine levels through vitamin 
administration on cardiovascular disease risk or recurrence50, 51. Since homocysteine is 
part of a larger metabolic network that provides substrates for many biological 
functions (methylation reactions, nucleotide biosynthesis, provision of folate cofactor 
forms), functional genetic polymorphisms in the genes of the network might exert 
their effect through pathways other than methionine biosynthesis.  
The Normative Aging Study is a prospective cohort study that has collected 
extensive lifestyle and medical data on its participants. The prospective nature of the 
NAS cohort minimizes the biases associated with case-control studies of 
cardiovascular disease. A potential weakness of this study is the availability of 
biomarker data on a subset of the full cohort only.  
In summary, we have investigated the role of the MTR 2756A→G and MTHFR 
677C→T polymorphisms in relation to serum homocysteine level and cardiovascular 
disease risk. There is some evidence for a gene-gene interaction such that the effect of 
the MTHFR 1298A→C genotype is limited to men with the MTHFR variant genotype. 
The observed effects are independent of homocysteine. Evaluation of this interaction 
in future epidemiologic studies and inclusion of multiple markers on MTHFR gene 
including the MTHFR 1298, are recommended. 
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